Chimeric FcεRIα chain gene, chimeric FcεRIα chain protein, cells, analysis kit, and analysis method

The chimeric FcεRIα chain gene enhances allergy test sensitivity by combining human and non-human animal FcεRIα chain domains, improving detection of allergens and anti-allergic substances in allergy tests.

JP7587745B2Active Publication Date: 2024-11-21神奈川県 +2
View PDF 1 Cites 0 Cited by

Patent Information

Application Number
JP2023503758
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Priority Date
2021-03-01
Filing Date
2022-02-24
Publication Date
2024-11-21
Estimated Expiration
2042-02-24

AI Technical Summary

Technical Problem

Current allergy test methods lack sufficient sensitivity, particularly in detecting trace allergens and evaluating the biological significance of patient IgE, leading to issues such as false positives and negatives.

Method used

A chimeric FcεRIα chain gene is developed, combining the extracellular domain of the human FcεRIα chain with the cell membrane-spanning and intracellular domains of a non-human animal FcεRIα chain, which is used to create a chimeric FcεRIα chain protein expressed in cells, forming aggregates with FcεRI γ chains to enhance sensitivity in allergy tests.

Benefits of technology

The chimeric FcεRIα chain gene significantly improves the sensitivity of allergy tests, allowing for high-throughput screening of anti-allergic substances and accurate detection of allergens, reducing false positives and negatives.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007587745000017
    Figure 0007587745000017
  • Figure 0007587745000018
    Figure 0007587745000018
  • Figure 0007587745000019
    Figure 0007587745000019
Patent Text Reader

Abstract

The purpose of the present invention is to provide a means for improving allergy test sensitivity. Provided is a chimeric FcεRI α-chain gene that contains a first base sequence encoding the extracellular domain of human FcεRI α-chain and a second base sequence encoding at least the cell transmembrane domain of a non-human animal FcεRI α-chain. Also provided are a chimeric FcεRI α-chain protein that is the expression product of the chimeric FcεRI α-chain gene, and non-human animal cells containing the chimeric FcεRI α-chain gene. Also provided are an analysis kit containing the cells and an analysis method using the cells.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to a chimeric FcεRIα chain gene, a chimeric FcεRIα chain protein, cells, an analytical kit, and an analytical method, and more particularly to a chimeric FcεRIα chain gene, a chimeric FcεRIα chain protein, cells, and a kit used for performing allergy-related tests, and an allergy-related analytical method. [Background technology]

[0002] IgE, which is involved in allergic reactions, is an antibody that exists in very small amounts in serum. IgE binds very tightly (Ka=10 10 M -1 FcεRI may contain one α chain, one β chain, and a homodimer of the γ chain. In most animal species, these subunits are expressed on the cell membrane only after forming a tetramer, but in humans, an expression pattern without the β chain is also known.

[0003] When B cells produce allergen (antigen)-specific IgE, the IgE enters the bloodstream and binds to FcεRI expressed by peripheral immune cells, particularly mast cells and basophils, sensitizing these cells. When these IgE-sensitized cells are exposed to a specific antigen, the antigen and IgE bind. If multiple IgE epitopes are present on one antigen molecule, multiple IgE antibodies will bind via the antigen, resulting in multiple FcεRI being "cross-linked."

[0004] The cross-linking of FcεRI triggers cellular responses, such as calcium ion influx, degranulation of chemical mediators such as histamine, and enhanced production of lipid chemical mediators, through activation of enzymes such as tyrosine kinases associated with the intracellular domain of the receptor and adapter molecules, resulting in an immediate allergic response. Furthermore, gene expression, such as cytokines and chemokines, is induced through activation of certain transcription factors, which leads to a later stage of inflammatory reactions.

[0005] Several methods for testing allergies have been proposed. For example, the following Patent Document 1 discloses a method for testing whether a test substance is an allergen to a subject, comprising incubating a cell having an Fc receptor with affinity to human IgE on the cell membrane and having a promoter and a reporter gene in this order under the control of an enhancer to which a transcription factor can bind, in the presence of a biological sample from a subject; contacting the test substance with the cells after the incubation; and confirming an increase in the expression of the reporter gene in the cells contacted with the test substance. [Prior art documents] [Patent documents]

[0006] [Patent Document 1] JP 2011-19467 A Summary of the Invention [Problem to be solved by the invention]

[0007] There is a demand for further improvement in the sensitivity of allergy testing. If the sensitivity can be improved, it is considered to be useful for various allergy-related tests, such as evaluation based on the biological significance of patient IgE, detection of trace allergens, and high-throughput screening of antiallergic substances. Therefore, the main object of the present invention is to increase the sensitivity of allergy testing, particularly the sensitivity of IgE detection techniques. [Means for solving the problem]

[0008] The present invention relates to A first base sequence capable of encoding an extracellular domain of a human FcεRIα chain; a second base sequence capable of encoding at least a transmembrane domain of a non-human animal FcεRIα chain; The present invention provides a chimeric FcεRIα-chain gene comprising: The first base sequence may comprise a base sequence having 70% or more sequence identity with the base sequence of SEQ ID No.7. The second base sequence may comprise a base sequence having 70% or more sequence identity with the base sequence of SEQ ID No.5. The second base sequence may further comprise a base sequence having a sequence identity of 70% or more with the base sequence of SEQ ID No.6. The chimeric FcεRI α-chain gene may further comprise a third base sequence encoding a signal sequence for expressing the chimeric FcεRI α-chain generated based on the gene onto a cell membrane. The third base sequence may comprise a base sequence having 70% or more sequence identity with the base sequence of SEQ ID No.2. The chimeric FcεRI α-chain gene may have a nucleotide sequence that has 50% or more sequence identity with the nucleotide sequence of SEQ ID No.1. The non-human animal may be a rodent.

[0009] The present invention also provides a method for producing a semiconductor device comprising the steps of: an extracellular domain of the human FcεRIα chain; At least the transmembrane domain of the non-human animal FcεRIα chain Also provided is a chimeric FcεRI α chain protein comprising: The extracellular domain may comprise an amino acid sequence having 70% or more sequence identity with the amino acid sequence of SEQ ID No. 14. The transmembrane domain may comprise an amino acid sequence having 70% or more sequence identity with the amino acid sequence of SEQ ID No. 12. The chimeric FcεRIα chain protein further comprises an intracellular domain of a non-human animal FcεRIα chain, The intracellular domain may comprise an amino acid sequence having 70% or greater sequence identity to the amino acid sequence of SEQ ID No.13. The chimeric FcεRI α chain protein may have an amino acid sequence that has 70% or greater sequence identity to the amino acid sequence of SEQ ID No.8.

[0010] The present invention also provides a vector comprising the chimeric FcεRIα-chain gene.

[0011] The present invention also provides a cell of the non-human animal comprising the chimeric FcεRI α-chain gene, the chimeric FcεRI α-chain protein, or the vector. The cell may further comprise a gene for the γ-chain of FcεRI of the non-human animal cell. The cells can form an aggregate comprising a chimeric FcεRIα chain generated based on the chimeric FcεRIα chain gene and the FcεRI γ chain of the cells. The cells may further comprise a reporter gene whose expression is induced by crosslinking of the aggregates.

[0012] The present invention also provides an analytical kit comprising the cells.

[0013] The present invention also provides an analytical method using the cells. The analysis method includes: Incubating the cells; and an analyzing step for analyzing the response of said cells The method may include performing The incubating step may include incubating the cells in an incubation material. The analyzing step comprises: Evaluation of allergenicity, Assessment of the presence or risk of allergies, Analysis of IgE, Evaluation of allergy-suppressing activity, and Drug Screening The method may include performing at least one selected from the group consisting of: The step of analyzing may include assessing the presence or absence of, or risk of, type I allergy. [Brief description of the drawings]

[0014] [Figure 1] FIG. 1 is a schematic diagram illustrating a cell of the present invention. [Diagram 2] FIG. 1 is a schematic diagram illustrating the chimeric FcεRIα chain protein of the present invention. [Diagram 3] FIG. 1 shows examples of the construction of the chimeric FcεRIα-chain gene and chimeric FcεRIα-chain protein of the present invention. [Figure 4] FIG. 1 shows the nucleotide sequence of the chimeric FcεRIα-chain gene used in the Examples and the amino acid sequence encoded by the gene. [Diagram 5] This is the base sequence of sequence ID No. 15. [Figure 6] FIG. 1 illustrates sequences for gene insertion. [Figure 7] FIG. 13 is a diagram showing the results of measuring luminescence intensity. [Figure 8] FIG. 1 shows the results of measurement using a flow cytometer. [Figure 9] FIG. 13 is a diagram showing the results of measuring luminescence intensity. [Figure 10] FIG. 13 is a diagram showing the results of measuring luminescence intensity. [Figure 11] FIG. 13 is a graph showing the results of absorbance measurements. [Figure 12] FIG. 13 is a diagram showing the results of measuring luminescence intensity. [Figure 13] FIG. 13 is a diagram showing the results of measuring luminescence intensity. [Figure 14] FIG. 13 is a diagram showing the results of measuring luminescence intensity. [Figure 15] FIG. 13 is a diagram showing the results of measuring luminescence intensity. [Figure 16] FIG. 13 is a diagram showing the results of measuring luminescence intensity. [Figure 17] FIG. 13 is a diagram showing the results of measuring luminescence intensity. [Figure 18] FIG. 13 is a diagram showing the results of measuring luminescence intensity. [Figure 19] FIG. 1 is a schematic diagram illustrating the structure and function of the chimeric FcεRIα chain gene used in the Examples and the chimeric FcεRIα chain protein expressed from the gene. [Figure 20] FIG. 13 is a diagram showing the results of measuring luminescence intensity. [Figure 21] FIG. 13 is a diagram showing the results of measuring luminescence intensity. [Figure 22] FIG. 13 is a diagram showing the results of measuring luminescence intensity. [Figure 23] FIG. 13 is a diagram showing the results of measuring luminescence intensity. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0015] Preferred embodiments for carrying out the present invention will be described below. Note that the embodiments described below are representative embodiments of the present invention, and the scope of the present invention is not limited to these embodiments.

[0016] The present invention will be described in the following order. 1. Description of the Invention 2. First embodiment (chimeric FcεRIα-chain gene) (1) First base sequence (2) Second base sequence (3) The third base sequence (4) Entire chimeric FcεRIα chain gene 3. Second embodiment (chimeric FcεRIα chain protein) (1) Extracellular domain (2) Transmembrane domain and intracellular domain (3) Signal sequence (4) Chimeric FcεRIα chain protein 4. Third embodiment (vector) 5. Fourth embodiment (cells) 6. Fifth embodiment (analysis kit) 7. Sixth embodiment (analysis method) 8. Working Example (1) Synthesis of chimeric FcεRIα chain gene (2) Introduction of chimeric FcεRIα chain genes into RBL-NL4 cells (3) Luciferase expression in cells transfected with the chimeric FcεRIα chain gene (4) Confirmation of IgE binding ability to cells transfected with chimeric FcεRIα chain gene (5) Examination of test conditions suitable for the cells of the present invention (6) Testing using serum from allergy patients (peanut allergy) (7) Comparison of the cells of the present invention with other cells (allergy testing, egg allergy) (8) Comparison of the cells of the present invention with other cells (evaluation of the effectiveness of allergic reaction inhibitors) (9) Stability and reproducibility

[0017] 1. Description of the Invention

[0018] Allergy testing methods currently commonly used in clinical practice can be divided into three categories, for example, in vivo testing, ex vivo testing, and in vitro testing, each of which has its own advantages and disadvantages. In vivo testing is the most reliable because allergens are administered to the patient himself, but it has the problem of imposing a burden on the patient. In ex vivo testing, basophils from the patient can be taken out of the body and allergens can be administered to the basophils. The ex vivo testing method uses activation of basophils (e.g., release of histamine or expression of CD203c / CD63 on the cell surface) as an indicator, so it is highly reliable. However, the ex vivo testing method uses whole blood, so there is a problem that samples cannot be stored. One of the most frequently used in vitro testing methods is the ImmunoCAP method. The ImmunoCAP method can be performed using serum or plasma from the patient. The ImmunoCAP method is simple and relatively sensitive, but has the problem of a very high number of false positives. This problem may occur when there is only one IgE epitope on the allergen, and may also be due to the low binding affinity between the allergen and IgE, which is insufficient to maintain FcεRI cross-linking.

[0019] In the above-mentioned ex vivo test method, activation of basophils in a patient is quantified, but by slightly modifying this method, IgE-dependent activation of basophils in the patient's serum can be examined. That is, in this modified method, peripheral blood basophils are first isolated from a healthy subject, and the isolated basophils are treated with acid to dissociate the bound IgE from the basophils. The basophils are then passively sensitized with IgE in the serum from the subject, and the antigen-specific activation of basophils due to the sensitization is examined. However, this method is time-consuming, and since peripheral blood from the same healthy subject is not always available, there is a problem that the test lacks reproducibility.

[0020] As a method to solve such problems, several groups have devised a method in which a cultured cell line in which human FcεRI is stably expressed is used, for example, in RBL-2H3 cells, known as a cultured rat mast cell line, and the cell line is sensitized with serum from an allergy patient and the amount of degranulation measured when a specific antigen is added. This method was groundbreaking in the sense that it sensitized cultured mast cells expressing human FcεRI with IgE in the patient serum and was able to detect cross-linking of FcεRI by antigen. However, this method has a problem in that the sensitivity of the degranulation measurement is low and there is a high probability of false negative results.

[0021] The method described in Patent Document 1 can address these problems. In the method described in Patent Document 1, a cell is used that has an Fc receptor with affinity to human IgE on the cell membrane and a promoter and a reporter gene in this order under the control of an enhancer to which a transcription factor can bind. As an example of this cell, Patent Document 1 discloses a cell line RS-ATL8 cell in which a reporter gene that induces the expression of a firefly luciferase gene in a transcription factor Nuclear Factor of Activated T-cells (NF-AT)-dependent manner is introduced into RBL-SX38 cells, which are cultured cell lines in which human FcεRI is stably expressed in RBL-2H3 cells. In the method described in Patent Document 1, the cells are sensitized with IgE by culturing the cells overnight with, for example, 100-fold diluted patient serum, and after the sensitization, the cells are contacted with a specific antigen. The contact induces crosslinking of FcεRI. The crosslinking causes luciferase to be expressed via intracellular signal transduction involving the transcription factor. This allows for highly sensitive detection of antigens or specific IgE. This method is also called the "IgE-Crosslinking-induced Luciferase Expression (EXiLE) method." This method has a very simple protocol and is suitable for screening a large number of samples. Furthermore, this method has very good performance, for example, the area under the curve exceeds 0.97 in ROC curve analysis of patients with egg white allergy. Researchers around the world are already using this method, and as of August 2019, for example, it is being used in 16 countries, mainly in Europe and the United States.

[0022] Although the method described in Patent Document 1 can detect antigens and specific IgE with high sensitivity, there is a need for further improvement in sensitivity, which is considered to be useful for, for example, evaluation based on the biological significance of patient IgE, detection of trace allergens, and high-throughput screening of antiallergic substances.

[0023] The present inventors have found that a chimeric FcεRIα chain gene comprising a first base sequence encoding the extracellular domain of the human FcεRIα chain and a second base sequence encoding at least the transmembrane domain of the non-human animal FcεRIα chain is extremely useful for improving the sensitivity of allergy testing. For example, non-human animal cells (e.g., mast cells) into which the chimeric FcεRIα chain gene has been introduced are suitable for use in tests related to human allergies, and can be used, for example, as a material used for testing human allergies with high sensitivity. For example, the chimeric FcεRIα chain gene may be used, for example, in the method described in Patent Document 1, and in particular may be introduced into cells used in the method described in Patent Document 1.

[0024] An example of a cell having a chimeric FcεRIα-chain gene of the present invention and the mechanism of antigen or IgE detection by the cell will be described below with reference to FIGS.

[0025] The cell 1 shown in Fig. 1 is a non-human animal cell. The cell 1 comprises the chimeric FcεRIα chain gene of the present invention and a reporter gene. The cell 1 further comprises the FcεRIγ chain gene of the non-human animal cell. The non-human animal cell may further comprise the FcεRIβ chain gene of the non-human animal cell.

[0026] In cell 1, the chimeric FcεRIα chain gene, the FcεRIβ chain gene, and the FcεRIγ chain gene are expressed to generate chimeric FcεRIα chain protein, FcεRIβ chain protein, and FcεRIγ chain protein. Chimeric FcεRI, which is a tetramer formed by association of one chimeric FcεRIα chain protein, one FcεRIβ chain protein, and two FcεRIγ chain proteins (homodimer), is expressed on the cell membrane surface of cell 1 as shown in Figure 1. In dendritic cells, chimeric FcεRI is expressed in a trimeric conformation consisting of one α chain and two γ chains.

[0027] A more detailed schematic diagram of the chimeric FcεRI is shown in FIG. 2A. As shown in FIG. 2A, the chimeric FcεRI is composed of a chimeric FcεRIα chain protein ( h+r α), FcεRIβ chain protein (indicated in the figure r β) and a homodimer of FcεRIγ chain protein ( r The α-chain protein is a tetramer consisting of a first portion (shown in dots in the figure) derived from a human FcεRIα chain and a second portion (shown in gray in the figure) derived from a non-human animal FcεRIα chain. It should be understood that FIGS. 1 and 2 are schematic diagrams for the purpose of explanation and do not reflect the actual state.

[0028] The first portion includes an extracellular domain of a human FcεRIα chain. The extracellular domain may literally be exposed outside the cell. The extracellular domain includes an IgE-binding region of a human FcεRIα chain. For example, as shown in FIG. 2A, the extracellular domain is present outside the cell, and the α chain protein binds human IgE( h It can bind to IgE.

[0029] The second part comprises at least a transmembrane domain of a non-human animal FcεRIα chain. The transmembrane domain also comprises one or more amino acid residues that contribute to binding to a non-human animal FcεRIγ chain, e.g., that exert the binding ability. The second part may further comprise an intracellular domain of the non-human animal FcεRIα chain. For example, as shown in Figure 2A, the α chain protein may bind to the γ chain protein via the one or more amino acid residues of the transmembrane domain, and as shown in the figure, the α chain protein is anchored to the cell membrane by the transmembrane domain.

[0030] The FcεRI β chain protein may be the expression product of the FcεRI β chain gene endogenously present in the non-human animal. The FcεRI γ-chain protein may also be the expression product of the FcεRI γ-chain gene endogenously present in the non-human animal.

[0031] A schematic diagram of FcεRI expressed by the above-mentioned RS-ATL8 cells is shown in FIG. 2B. RS-ATL8 cells are RBL-SX38 cells in which human FcεRI is stably expressed in RBL-2H3 cells and an NF-AT-dependent firefly luciferase expression vector is stably introduced. As shown in FIG. 2B, the α-chain and γ-chain of FcεRI expressed in RS-ATL8 cells are those of human FcεRI (parts shown by dots), and the β-chain is thought to be that of rat FcεRI (parts shown in gray). Since the α-chain of FcεRI expressed in RS-ATL8 cells is that of human FcεRI, it can bind to human IgE. Whereas the α-chain of FcεRI in RS-ATL8 cells is entirely that of human FcεRI, the chimeric FcεRI α-chain protein of the present invention in Figure 2A has an extracellular domain that is human FcεRI while the transmembrane domain is that of a non-human animal's FcεRI.

[0032] A schematic diagram of FcεRI expressed by the above-mentioned RBL-2H3 cells is shown in Figure 2C. The α-chain, β-chain, and γ-chain of the FcεRI are all derived from rats, and the α-chain binds to rat IgE.

[0033] As shown in Figure 1, type I allergy is caused by (1) binding of FcεRI and IgE (sensitization), (2) binding of an antigen (allergen) to IgE and IgE bound to FcεRI (binding), (3) cross-linking between multiple IgE-bound FcεRI bound to a single antigen (cross-linking), (4) release of physiologically active substances such as histamine and serotonin from cells (degranulation), and (5) a systemic response caused by the physiologically active substance.

[0034] By confirming the expression of the reporter gene whose expression is induced by the cross-linking between multiple IgE-bound FcεRIs as described above in (3), it is possible to detect, for example, an antigen (particularly a specific antigen) that binds to IgE.

[0035] 2. First embodiment (chimeric FcεRIα-chain gene)

[0036] An example of the construction of a chimeric FcεRIα-chain gene of the present invention is described below with reference to Figure 3A. Figure 3A is a schematic diagram for explaining the construction of a chimeric FcεRIα-chain gene of the present invention. In Figure 3A, the left side of the page is the 5'-end of the gene, and the right side is the 3'-end of the gene. Also shown below the schematic diagram is Figure 3B, which shows an example of the structure of a chimeric FcεRIα chain protein of the present invention generated by expression of a chimeric FcεRIα chain gene of the present invention. In Figure 3B, the left side of the page is the N-terminus of the protein, and the right side is the C-terminus of the protein.

[0037] As shown in Figure 3A, the chimeric FcεRIα chain gene of the present invention comprises a first base sequence encoding the extracellular domain of the human FcεRIα chain and a second base sequence encoding at least the transmembrane domain of the non-human animal FcεRIα chain. The second base sequence particularly encodes the transmembrane domain and the intracellular domain of the non-human animal FcεRIα chain, and the transmembrane domain is capable of binding to the non-human animal FcεRIγ chain. The chimeric FcεRI α-chain gene of the present invention may further comprise a third base sequence encoding a signal sequence for expressing the chimeric FcεRI α-chain produced based on the gene onto a cell membrane. As shown in Figure 3B, the chimeric FcεRIα chain protein produced by expression of the chimeric FcεRIα chain gene of the present invention may comprise the extracellular domain 1 of the human FcεRIα chain, and the transmembrane domain 2 and intracellular domain 3 of the non-human animal FcεRIα chain. The extracellular domain 1 may comprise an IgE-binding region. The transmembrane domain 2 may exhibit binding ability to the non-human animal FcεRIγ chain and may comprise one or more amino acid residues exhibiting said binding ability. The chimeric FcεRIα chain protein may further comprise a signal sequence 4 for expressing the protein on a cell membrane. As described above, the first base sequence contained in the chimeric FcεRIα chain gene corresponds to the extracellular domain contained in the chimeric FcεRIα chain protein, the second base sequence corresponds to the transmembrane domain and the intracellular domain, and the third base sequence corresponds to the signal sequence.

[0038] As shown in FIG. 3A, the first to third base sequences may be arranged in the order of the third base sequence, the first base sequence, and the second base sequence from the 5' end. The extracellular domain, the transmembrane domain, the intracellular domain, and the signal sequence may be arranged in the following order from the N-terminus: the signal sequence, the extracellular domain, the transmembrane domain, and the intracellular domain, as shown in Figure 3B. In addition, one or more amino acid residues may or may not be inserted between these regions.

[0039] (1) First base sequence

[0040] As described above, the first base sequence encodes the extracellular domain of the human FcεRIα chain. The extracellular domain includes an IgE-binding region of the human FcεRIα chain. The IgE-binding region may be a region that binds to human IgE.

[0041] The first base sequence preferably comprises a base sequence having sequence identity of 70% or more, more preferably 80% or more, even more preferably 85% or more, particularly preferably 90% or more, 92% or more, 94% or more, 95% or more, 96% or more, 97% or more, 98% or more, or 99% or more to the base sequence of SEQ ID No. 7. The amino acid sequence encoded by the base sequence is preferred for binding to IgE and functions as an IgE-binding region.

[0042] SEQ ID No. 7 is as follows: SEQ ID No. 7 is a nucleotide sequence corresponding to amino acid residues 110 to 183 in the amino acid sequence of SEQ ID No. 8 (the chimeric FcεRIα chain protein of the present invention) described below.

[0043] JPEG0007587745000001.jpg44163

[0044] In a more preferred embodiment, the first base sequence may comprise a base sequence having sequence identity of 70% or more, more preferably 80% or more, even more preferably 85% or more, particularly preferably 90% or more, 92% or more, 94% or more, 95% or more, 96% or more, 97% or more, 98% or more, or 99% or more to the base sequence of SEQ ID No. 3 below. The amino acid sequence encoded by the base sequence is preferred for binding to IgE, and is also preferred for maintaining a structure that provides IgE binding. The amino acid sequence encoded by the base sequence may constitute the entire extracellular domain of the chimeric FcεRIα chain protein of the present invention. SEQ ID No. 3 is a base sequence corresponding to amino acid residues 26 to 205 in the amino acid sequence of SEQ ID No. 8 (the chimeric FcεRIα chain protein of the present invention) described below.

[0045] JPEG0007587745000002.jpg85165

[0046] The first base sequence may also encode two amino acid sequences that function as immunoglobulin domains. One of the two amino acid sequences is the amino acid sequence of amino acid residues 44 to 108 in the amino acid sequence of SEQ ID No. 8 (the chimeric FcεRIα chain protein of the present invention). A base sequence encoding this amino acid sequence corresponds to, for example, bases 130 to 324 in SEQ ID No. 1. The other of the two amino acid sequences is the amino acid sequence of amino acid residues 121 to 194 in the amino acid sequence of SEQ ID No. 8. The base sequence encoding this amino acid sequence corresponds to, for example, bases 361 to 582 in SEQ ID No. 1. The region between these two amino acid sequences, which functions as an immunoglobulin domain, is also called a linker region. The linker region is the amino acid sequence of amino acid residues 109 to 120 in the amino acid sequence of SEQ ID No. 8. The base sequence encoding the linker region corresponds to, for example, bases 325 to 360 in SEQ ID No. 1. For these base sequences, sequence identity is permitted as described above for SEQ ID No. 3.

[0047] In this specification, the "sequence identity" of a base sequence (or amino acid sequence) refers to the percentage obtained by aligning two base sequences (or amino acid sequences) to be compared so that as many bases (or amino acid residues) as possible match, and dividing the number of matching bases (or the number of matching amino acid residues) by the total number of bases (or the total number of amino acid residues). The alignment and calculation of the percentage may be performed using a well-known algorithm such as BLAST.

[0048] (2) Second base sequence

[0049] As described above, the second base sequence encodes at least the cell transmembrane domain of the non-human animal FcεRI α chain. The cell transmembrane domain has a function of binding to the γ chain. To exert this function, the cell transmembrane domain may contain amino acid residues involved in binding to the γ chain of the non-human animal FcεRI. For example, Asp contained in the cell transmembrane domain described below may be involved in the binding. The non-human animal is, for example, a rodent, preferably a rat, a mouse, or a hamster, more preferably a rat or a mouse, and particularly preferably a rat.

[0050] Furthermore, the second base sequence may further encode a region containing the intracellular domain of the non-human animal FcεRIα chain in addition to the transmembrane domain.

[0051] Particularly preferably, the second base sequence may encode a region of the non-human animal FcεRIα chain that includes both the transmembrane domain and the intracellular domain. The transmembrane domain may have a function of binding to the non-human animal FcεRIγ chain and may include the Asp for exerting the function. The Asp may be Asp at amino acid number 219 in SEQ ID No. 12 described below.

[0052] The second base sequence is preferably A nucleotide sequence having a sequence identity of 70% or more, more preferably 80% or more, even more preferably 85% or more, particularly preferably 90% or more, 92% or more, 94% or more, 95% or more, 96% or more, 97% or more, 98% or more, or 99% or more with the nucleotide sequence of SEQ ID No. 5; and A nucleotide sequence having a sequence identity of 70% or more, more preferably 80% or more, even more preferably 85% or more, particularly preferably 90% or more, 92% or more, 94% or more, 95% or more, 96% or more, 97% or more, 98% or more, or 99% or more with the nucleotide sequence of SEQ ID No. 6. The amino acid sequence encoded by such a base sequence is preferred for binding to a non-human animal FcεRIγ chain. The nucleotide sequence having the sequence identity with the nucleotide sequence of SEQ ID No. 5 corresponds to the transmembrane domain of a non-human animal FcεRIα chain. The nucleotide sequence having the sequence identity with the nucleotide sequence of SEQ ID No. 6 corresponds to the intracellular domain of a non-human animal FcεRIα chain.

[0053] Sequence ID No. 5 and Sequence ID No. 6 are as follows: SEQ ID No. 5 is a base sequence corresponding to amino acid residues 206 to 224 (transmembrane domain) in the amino acid sequence of SEQ ID No. 8 (the chimeric FcεRIα chain protein of the present invention) described below. Sequence ID No. 6 is a base sequence corresponding to amino acid residues 225 to 246 (intracellular domain) of the amino acid sequence.

[0054] JPEG0007587745000003.jpg30162

[0055] JPEG0007587745000004.jpg33159

[0056] Of the second base sequence, the base sequence having sequence identity with the base sequence of SEQ ID No. 5 is located at the 5'-end, and the base sequence having sequence identity with the base sequence of SEQ ID No. 6 is located at the 3'-end. No base sequence may be inserted between these two base sequences (i.e., the latter base sequence may be located immediately after the former base sequence), but for example, 15 to 75 bases (corresponding to 5 to 25 amino acid residues), particularly 21 to 60 bases (corresponding to 7 to 20 amino acid residues), more particularly 30 to 45 bases (corresponding to 10 to 15 amino acid residues), and more particularly 36 bases (corresponding to 12 amino acid residues) may be inserted.

[0057] The second base sequence encoding a region including both the transmembrane domain and the intracellular domain comprises a base sequence having sequence identity of 70% or more, more preferably 80% or more, even more preferably 85% or more, particularly preferably 90% or more, 92% or more, 94% or more, 95% or more, 96% or more, 97% or more, 98% or more, or 99% or more to the base sequence of SEQ ID No. 4. An amino acid sequence encoded by such a base sequence is preferred for binding to a non-human animal FcεRIγ chain. Sequence ID No. 4 is as follows: Sequence ID No. 4 is a base sequence corresponding to amino acid residues 206 to 246 (transmembrane domain and intracellular domain) in the amino acid sequence of Sequence ID No. 8 (the chimeric FcεRIα chain protein of the present invention) described below.

[0058] JPEG0007587745000005.jpg32161

[0059] (3) The third base sequence

[0060] As described above, the third base sequence encodes a signal sequence for expressing the chimeric FcεRIα chain generated based on the gene on a cell membrane. For example, it may encode a signal sequence for causing the chimeric FcεRIα chain protein to penetrate the cell membrane (particularly, penetrate the membrane once). In one embodiment of the present invention, the signal sequence may be, for example, a signal sequence contained in a human FcεRIα chain protein or a signal sequence contained in a non-human animal FcεRIα chain protein. Preferably, the signal sequence is a signal sequence contained in a human FcεRIα chain protein. The chimeric FcεRIα chain protein produced from the chimeric FcεRIα chain gene of the present invention is expressed on a cell membrane by the signal sequence encoded in the third base sequence. In another embodiment of the present invention, the signal sequence may be a signal sequence contained in Igκ, for example, a signal sequence contained in human Igκ or non-human animal Igκ. The signal sequence also enables the chimeric FcεRIα-chain protein to be expressed on the cell membrane.

[0061] The third base sequence is preferably The chimeric FcεRIα chain protein includes a nucleotide sequence having 70% or more, more preferably 80% or more, even more preferably 85% or more, and particularly preferably 90% or more, 92% or more, 94% or more, 95% or more, 96% or more, 97% or more, 98% or more, or 99% or more sequence identity to the nucleotide sequence of SEQ ID No. 2. Such a nucleotide sequence is preferred for expression of the chimeric FcεRIα chain protein on a cell membrane.

[0062] Sequence ID No. 2 is as follows: Sequence ID No. 2 is a nucleotide sequence corresponding to amino acid residues 1 to 25 (signal sequence) in the amino acid sequence of Sequence ID No. 8 (the chimeric FcεRIα chain protein of the present invention) described below.

[0063] JPEG0007587745000006.jpg32164

[0064] (4) Entire chimeric FcεRIα chain gene

[0065] The chimeric FcεRIα chain gene of the present invention preferably has a base sequence that has a sequence identity of 50% or more, more preferably 60% or more, even more preferably 70% or more, even more preferably 80% or more, even more preferably 85% or more, and particularly preferably 90% or more, 92% or more, 94% or more, 95% or more, 96% or more, 97% or more, 98% or more, or 99% or more to the base sequence of sequence ID No. 1.

[0066] SEQ ID No. 1 is as follows: SEQ ID No. 1 is a nucleotide sequence encoding the amino acid sequence of SEQ ID No. 8 (the chimeric FcεRIα chain protein of the present invention) described below.

[0067] JPEG0007587745000007.jpg120160

[0068] Sequence ID No. 1 to No. 7 are optimized taking into consideration the codon usage frequency of rodents, particularly rats, and therefore the non-human animal is preferably a rodent, more preferably a rat, mouse, or hamster, and particularly preferably a rat.

[0069] (Manufacturing method) The chimeric FcεRI α-chain gene of the present invention can be produced, for example, by artificial gene synthesis techniques known in the art. For example, the chimeric FcεRI α-chain gene can be produced by chemical synthesis or enzymatic methods. In addition, the chimeric FcεRIα-chain gene of the present invention may be produced by combining multiple gene components using restriction enzymes and / or PCR, or may be produced by genome editing of the FcεRIα-chain gene of non-human animal cells (particularly rat cells).

[0070] 3. Second embodiment (chimeric FcεRIα chain protein)

[0071] An example of the structure of a chimeric FcεRIα chain protein of the present invention is shown in Figure 3B. This example structure is as explained in "2. First embodiment (chimeric FcεRIα chain gene)" above. That is, the chimeric FcεRIα chain protein comprises the extracellular domain of the human FcεRIα chain and the transmembrane domain of the non-human animal FcεRIα chain. The chimeric FcεRIα chain protein may further comprise the intracellular domain of the non-human animal FcεRIα chain. The extracellular domain may include an IgE-binding region of the human FcεRIα chain, and the transmembrane domain may contribute to the binding of the non-human animal FcεRIα chain to the non-human animal FcεRIγ chain. Furthermore, the chimeric FcεRIα chain protein may further comprise a signal sequence for expressing the protein on a cell membrane.

[0072] (1) Extracellular domain

[0073] The extracellular domain includes the IgE-binding region, which may be a region of the human FcεRIα chain that binds to human IgE, as described above. The extracellular domain may correspond to, for example, the first base sequence contained in the chimeric FcεRIα chain gene of the present invention described above. In other words, the extracellular domain may have an amino acid sequence encoded by the first base sequence.

[0074] The extracellular domain may preferably comprise an amino acid sequence having a sequence identity of 70% or more, more preferably 80% or more, even more preferably 85% or more, particularly preferably 90% or more, 92% or more, 94% or more, 95% or more, 96% or more, 97% or more, 98% or more, or 99% or more to the amino acid sequence of SEQ ID No. 14. Such an amino acid sequence functions as the IgE-binding region.

[0075] SEQ ID No. 14 is as follows: SEQ ID No. 14 corresponds to amino acid residues 110 to 183 of the amino acid sequence of SEQ ID No. 8 (the chimeric FcεRIα chain protein of the present invention) described below. The amino acid sequence of SEQ ID No. 14 is also the amino acid sequence encoded by the base sequence of SEQ ID No. 7.

[0076] JPEG0007587745000008.jpg45170

[0077] In a more preferred embodiment, the extracellular domain may be an amino acid sequence having sequence identity of 70% or more, more preferably 80% or more, even more preferably 85% or more, particularly preferably 90% or more, 92% or more, 94% or more, 95% or more, 96% or more, 97% or more, 98% or more, or 99% or more with the amino acid sequence of SEQ ID No. 10 below. Such an amino acid sequence is preferred for binding to IgE and also for maintaining a structure that provides IgE binding. Such an amino acid sequence may constitute the entire extracellular domain of the chimeric FcεRIα chain protein of the present invention. SEQ ID No. 10 is the amino acid sequence of amino acid residues 26 to 205 of the amino acid sequence of SEQ ID No. 8 (the chimeric FcεRIα chain protein of the present invention) described below.

[0078] JPEG0007587745000009.jpg81164

[0079] The extracellular domain may comprise two immunoglobulin domains. One of the two immunoglobulin domains may be formed by the amino acid sequence of amino acid residues 44 to 108 of the amino acid sequence of SEQ ID No. 8 (the chimeric FcεRIα chain protein of the present invention). The other of the two immunoglobulin domains may be formed by the amino acid sequence of amino acid residues 121 to 194 of the amino acid sequence of SEQ ID No. 8. The region between these two amino acid sequences functioning as an immunoglobulin domain is also called a linker region, and may be formed by the amino acid sequence of amino acid residues 109 to 120 of the amino acid sequence of SEQ ID No. 8. For these amino acid sequences, sequence identity is permitted as described above for SEQ ID No. 10. Such amino acid sequences are suitable for binding to IgE.

[0080] (2) Transmembrane domain and intracellular domain

[0081] The transmembrane domain may have a function of binding to the non-human animal FcεRIγ chain. To exert this function, the transmembrane domain may contain one or more amino acid residues that exert this function. For example, Asp contained in the transmembrane domain described below may be involved in this binding.

[0082] That is, the chimeric FcεRIα chain protein of the present invention may contain at least the transmembrane domain of a non-human animal FcεRIα chain. The transmembrane domain may contain one or more amino acid residues that function in binding to the non-human animal FcεRIγ chain. The transmembrane domain may contain, for example, the Asp as such an amino acid residue.

[0083] Furthermore, the chimeric FcεRIα chain protein of the present invention may further comprise the intracellular domain of the non-human animal FcεRIα chain. Particularly preferably, the chimeric FcεRIα chain protein of the present invention comprises both the transmembrane domain and the intracellular domain of the non-human animal FcεRIα chain.

[0084] The transmembrane domain may preferably comprise an amino acid sequence having a sequence identity of 70% or more, more preferably 80% or more, even more preferably 85% or more, and particularly preferably 90% or more, 92% or more, 94% or more, 95% or more, 96% or more, 97% or more, 98% or more, or 99% or more to the amino acid sequence of SEQ ID No. 12. The amino acid sequence having said sequence identity with the amino acid sequence of SEQ ID No. 12 corresponds to the transmembrane domain of a non-human animal FcεRIα chain.

[0085] The intracellular domain may preferably comprise an amino acid sequence having a sequence identity of 70% or more, more preferably 80% or more, even more preferably 85% or more, particularly preferably 90% or more, 92% or more, 94% or more, 95% or more, 96% or more, 97% or more, 98% or more, or 99% or more with the amino acid sequence of SEQ ID No. 13. Such an amino acid sequence is preferred for binding to a non-human animal FcεRIγ chain. The amino acid sequence having said sequence identity with the amino acid sequence of SEQ ID No. 13 corresponds to the intracellular domain of a non-human animal FcεRI α chain.

[0086] Sequence ID No. 12 and Sequence ID No. 13 are as follows: SEQ ID No. 12 corresponds to amino acid residues 206 to 224 (transmembrane domain) of the amino acid sequence of SEQ ID No. 8 (the chimeric FcεRIα chain protein of the present invention) described below. The amino acid sequence of SEQ ID No. 12 is also the amino acid sequence encoded by the base sequence of SEQ ID No. 5. SEQ ID No. 13 is a base sequence corresponding to amino acid residues 225 to 246 (intracellular domain) of the amino acid sequence, and is also an amino acid sequence encoded by the base sequence of SEQ ID No. 6.

[0087] JPEG0007587745000010.jpg25162

[0088] JPEG0007587745000011.jpg30161

[0089] From the viewpoint of good binding ability to non-human animal FcεRI γ-chain, the chimeric FcεRI α-chain protein of the present invention may contain both the amino acid sequence of SEQ ID NO:12 and the amino acid sequence of SEQ ID NO:13.

[0090] The amino acid sequence having sequence identity with the amino acid sequence of SEQ ID No. 12 may be located at the N-terminus, and the amino acid sequence having sequence identity with the amino acid sequence of SEQ ID No. 13 may be located at the C-terminus. No amino acid residues may be inserted between these two amino acid sequences (i.e., the latter amino acid sequence may immediately follow the former amino acid sequence), but for example, 5 to 25 amino acid residues, particularly 7 to 20 amino acid residues, more particularly 10 to 15 amino acid residues, and more particularly 12 amino acid residues may be inserted.

[0091] When the chimeric FcεRIα chain protein of the present invention comprises both the transmembrane domain and the intracellular domain of the non-human animal FcεRIα chain, the protein may preferably comprise an amino acid sequence having sequence identity of 70% or more, more preferably 80% or more, even more preferably 85% or more, and particularly preferably 90% or more, 92% or more, 94% or more, 95% or more, 96% or more, 97% or more, 98% or more, or 99% or more to the amino acid sequence of SEQ ID No. 11. The amino acid sequence having said sequence identity with the amino acid sequence of SEQ ID No. 11 corresponds to the transmembrane and intracellular domains of a non-human animal FcεRI α-chain. Sequence ID No. 11 is as follows:

[0092] JPEG0007587745000012.jpg34164

[0093] SEQ ID No. 11 corresponds to amino acid residues 206 to 246 (transmembrane domain and intracellular domain) of the amino acid sequence of SEQ ID No. 8 (the chimeric FcεRIα chain protein of the present invention) described below. The amino acid sequence of SEQ ID No. 11 is also the amino acid sequence encoded by the base sequence of SEQ ID No. 4.

[0094] (3) Signal sequence

[0095] As described above, the signal sequence is a signal sequence for expressing the chimeric FcεRIα chain on the cell membrane. The signal sequence promotes translocation of the chimeric FcεRIα chain protein of the present invention to the cell membrane.

[0096] The signal sequence preferably comprises an amino acid sequence having a sequence identity of 70% or more, more preferably 80% or more, even more preferably 85% or more, particularly preferably 90% or more, 92% or more, 94% or more, 95% or more, 96% or more, 97% or more, 98% or more, or 99% or more to the amino acid sequence of SEQ ID No. 9. Such an amino acid sequence is preferred for expression of the chimeric FcεRIα chain protein on the cell membrane.

[0097] SEQ ID No. 9 is as follows: SEQ ID No. 9 corresponds to amino acid residues 1 to 25 (signal sequence) of the amino acid sequence of SEQ ID No. 8 (the chimeric FcεRIα chain protein of the present invention) described below. The amino acid sequence of SEQ ID No. 9 is also the amino acid sequence encoded by the base sequence of SEQ ID No. 2.

[0098] JPEG0007587745000013.jpg26162

[0099] (4) Chimeric FcεRIα chain protein

[0100] The chimeric FcεRIα chain protein of the present invention preferably has an amino acid sequence that has a sequence identity of 70% or more, more preferably 80% or more, even more preferably 85% or more, and particularly preferably 90% or more, 92% or more, 94% or more, 95% or more, 96% or more, 97% or more, 98% or more, or 99% or more to the amino acid sequence of SEQ ID No. 8.

[0101] Sequence ID No. 8 is as follows:

[0102] JPEG0007587745000014.jpg120160

[0103] Furthermore, the chimeric FcεRI α chain protein of the present invention may further comprise the intracellular domain of a non-human animal FcεRI γ chain, whereby the α chain protein can fulfill the role of the γ chain in a cell in which the chimeric FcεRI α chain protein of the present invention is expressed, and the γ chain may not be expressed in the cell. Furthermore, the chimeric FcεRIα chain protein of the present invention may further comprise a kinase domain of a tyrosine kinase such as Lyn or Syk. The kinase domain may be inserted downstream of the amino acid sequence having sequence identity with the amino acid sequence of SEQ ID No. 13. The kinase domain can regulate signal transduction in cells in which the chimeric FcεRIα chain protein of the present invention is expressed, and can control allergic responses such as degranulation. These components enable induction of intracellular signaling independent of the gamma chain or tyrosine kinase of the host cell. When these components are included, the chimeric FcεRIα chain protein may preferably contain, for example, the transmembrane domain of CD8 or IL2Ra as the transmembrane domain for said induction.

[0104] The chimeric FcεRIα chain protein of the present invention can be produced using the chimeric FcεRIα chain gene of the present invention. For example, the chimeric FcεRIα chain protein of the present invention can be produced by expressing the chimeric FcεRIα chain gene of the present invention in a cell of a non-human animal from which the transmembrane domain encoded by the second base sequence contained in the gene is derived. For example, the chimeric FcεRIα chain protein of the present invention can be expressed in the cell membrane of a cell into which the gene has been introduced.

[0105] 4. Third embodiment (vector)

[0106] The present invention also provides a vector comprising the chimeric FcεRIα-chain gene. The gene can be introduced into a non-human animal cell by the vector. The vector may or may not be linearized when introduced into a non-human animal cell.

[0107] The vector may be prepared, for example, by inserting the chimeric FcεRI α-chain gene into a plasmid known in the art, e.g., the plasmid has at least one cloning site through which the chimeric FcεRI α-chain gene can be inserted into the plasmid.

[0108] The type of plasmid may be appropriately selected by those skilled in the art depending on the type of non-human animal cell, and an example of the plasmid is the pcDNA3.1(+) vector (Invitrogen).

[0109] The vector of the present invention may contain, for example, a Kozak sequence. The Kozak sequence can increase the efficiency of translation initiation. The Kozak sequence may be composed of, for example, the start codon of the chimeric FcεRIα-chain gene, 1 to 6 bases immediately before the start codon (5' end side), and 1 to 6 bases (particularly 1 base) immediately after the start codon (3' end side).

[0110] 5. Fourth embodiment (cells)

[0111] The present invention also provides a non-human animal cell comprising the chimeric FcεRI α-chain gene, the chimeric FcεRI α-chain protein, or the vector.

[0112] The chimeric FcεRI α-chain gene may, for example, be integrated into a chromosome of a cell of the non-human animal, or may be integrated into a vector introduced into a cell of the non-human animal. For stable expression, the chimeric FcεRI α-chain gene is preferably integrated into a chromosome of a cell of the non-human animal.

[0113] The cell of the present invention preferably further comprises a gene for the gamma chain of FcεRI of the non-human animal cell. Furthermore, the cell of the present invention can form an aggregate comprising a chimeric FcεRIα chain protein generated based on the chimeric FcεRIα chain gene and a gamma chain protein of FcεRI of the cell. The aggregate may comprise one of the α chains and two of the gamma chains. That is, a non-human animal FcεRIγ chain protein, which is an expression product of the gamma chain gene, can form an aggregate with the chimeric FcεRIα chain protein. The aggregate functions as an Fc receptor for human IgE and forms a complex that binds human IgE with high affinity. An antigen binds to multiple (e.g., two) of the IgEs, thereby crosslinking multiple (e.g., two) of the complexes, causing an allergic reaction. Thus, when the non-human cell further comprises the gamma chain gene, the non-human cell can induce an allergic reaction, which is useful for carrying out various allergy tests.

[0114] More preferably, the cell of the present invention further comprises a gene for the β-chain of FcεRI of the non-human animal cell. The β-chain of the non-human animal FcεRI generated based on the β-chain gene can enhance signal transduction by the cross-linking.

[0115] The gamma chain gene and the beta chain gene may be endogenous to the non-human animal, and may be naturally present in the chromosome of the non-human animal cell. For example, sequence information of rat gamma chain gene and beta chain gene is available from the NCBI Reference Sequence database. For example, information (including sequence information) of rat gamma chain gene is available from a web page (https: / / www.ncbi.nlm.nih.gov / nuccore / NM_001131001). Information (including sequence information) of rat beta chain gene is also available from a web page (https: / / www.ncbi.nlm.nih.gov / nuccore / M22923.1). Amino acid sequence information of proteins expressed from these genes can also be obtained from the uniprot database (https: / / www.uniprot.org / ).

[0116] The cell of the present invention can form an aggregate comprising a chimeric FcεRIα chain generated based on the chimeric FcεRIα chain gene, a β chain of the non-human animal FcεRI of the cell, and a γ chain of the non-human animal FcεRI of the cell. The aggregate may comprise one of the α chains, one of the β chains, and two of the γ chains. That is, the aggregate is a tetramer, and the cell of the present invention may preferably be configured to form the tetramer. The tetramer can enhance signal transduction involved in the allergic reaction. This allows allergy testing using the cell to be performed with higher sensitivity.

[0117] More preferably, the cell of the present invention further comprises a reporter gene whose expression is induced by crosslinking of the aggregates, and the reporter gene enables allergy testing using the cell to be carried out with high sensitivity.

[0118] As described above, the reporter gene is a gene whose expression is induced by crosslinking between the aggregates. The gene induced in this way can preferably be configured so that its expression is induced by a transcription factor activated by the crosslinking. The transcription factor may be any one selected from the group consisting of NF-AT, NF-κB, AP-1, Elk-1, Egr-1, GATA-1, and GATA-2, and is preferably NF-AT. Activation of NF-AT is suitable for detecting allergens that may induce type I allergy in subjects from among test substances.

[0119] For example, the reporter gene may be under the control of an enhancer to which the activating transcription factor can bind. A promoter may be located upstream of the reporter gene. For example, the cell of the present invention includes the enhancer, and a promoter and a reporter gene under the control of the enhancer. The enhancer, the promoter, and the reporter gene may be introduced into the cell by a vector (e.g., a plasmid) having a region including these three elements (hereinafter also referred to as a "reporter gene region"). The reporter gene region may be introduced into a chromosome of the non-human animal cell, or may be present in a vector in the non-human animal cell. Preferably, the reporter gene region is introduced into a chromosome of the non-human animal cell. This allows stable expression of the reporter gene. The reporter gene region may be introduced into a chromosome by, for example, homologous recombination.

[0120] The enhancer sequence may be appropriately selected by those skilled in the art depending on the type of the transcription factor, and may be, for example, any of the sequences shown in Table 1 below. Enhancer sequences are listed in the left column of Table 1 below. Each enhancer sequence is enclosed in parentheses, and the numbers listed outside the parentheses are examples of the number of repeats of the enhancer sequence. In the present technology, the number of repeats of the enhancer sequence of the enhancer contained in the reporter gene is not limited to the numbers listed in Table 1, and may be, for example, any number of 1 to 15, 2 to 15, particularly 2 to 10, and more particularly 3 to 10. The right column of Table 1 lists the transcription factors that bind to each enhancer sequence.

[0121] [Table 1]

[0122] The promoter may have a sequence to which a complex containing cellular RNA polymerase binds, for example a promoter having a TATA box, preferably a promoter having the sequence TATATAA.

[0123] The reporter gene may be, for example, any of the following: a gene encoding an enzyme, a gene encoding a fluorescent protein, and a gene encoding a surface antigen (not endogenous to the non-human animal). The gene encoding the enzyme may be, for example, any one or more of luciferase, β-galactosidase, alkaline phosphatase, chloramphenicol acetyltransferase, and horseradish peroxidase. The gene encoding the fluorescent protein may be, for example, any one or more of green fluorescent protein (GFP), Sirius, EBFP, ECFP, EGFP, Venus, and DsRed. The non-human animal cells of the present invention may have one or more reporter genes of the same or different types. Preferably, the non-human animal cells of the present invention may contain 1, 2, 3, 4 or 5 reporter genes.

[0124] The cell of the present invention may be a cell of a non-human animal. The non-human animal may be, for example, a rodent, preferably a rat, a mouse or a hamster, more preferably a rat.

[0125] The non-human animal cell of the present invention is preferably a cell configured so that the chimeric FcεRIα chain protein and the FcεRIγ chain protein derived from the non-human animal cell form an aggregate, more preferably a cell configured so that the chimeric FcεRIα chain protein and the FcεRIβ chain protein and the FcεRIγ chain protein derived from the non-human animal cell form an aggregate. Examples of such cells include mast cells (mast cells), basophils, dendritic cells, eosinophils, monocytes, macrophages, and Langerhans cells. That is, the cell of the present invention may be any one of these listed cells, more preferably a mast cell, basophil, or dendritic cell, and even more preferably a mast cell. The non-human animal cells of the present invention are preferably rat mast cells, basophils, or dendritic cells, or mouse mast cells, basophils, or dendritic cells, and more preferably rat or mouse mast cells.

[0126] The non-human animal cells of the present invention may be obtained, for example, by introducing the chimeric FcεRIα chain gene into cells isolated from an animal body or into established cell lines. Examples of the established cell lines that can be used in the present invention include, but are not limited to, rat mast cell line RBL-2H3 cells (cell number: JCRB0023, available from JCRB Cell Bank, National Institutes of Biomedical Innovation, Health and Nutrition, or cell number: CRL-2256, available from ATCC (trademark)) and mouse mast cell line MC / 9 cells (available from ATCC (trademark)).

[0127] The non-human animal cell of the present invention may be, for example, a cell deposited under the accession number: NITE BP-03230. The cell was internationally deposited at the National Institute of Technology and Evaluation (NPMD) Patent Microorganisms Depositary on June 17, 2020.

[0128] The non-human animal cells of the present invention may be used, for example, in an analytical method, such as the analytical method described below in "7. Sixth embodiment (analytical method)." Furthermore, the non-human animal cells of the present invention are suitable for use as cells in the method described in, for example, Patent Document 1. That is, the non-human animal cells of the present invention may be used in the EXiLE method described above.

[0129] 6. Fifth embodiment (analysis kit)

[0130] The present invention provides an analytical kit comprising the cell of the present invention. The kit can be used, for example, for analysis or diagnosis of allergy. The kit can be used, for example, for performing at least one test selected from the group consisting of evaluation of allergenicity, evaluation of the presence or absence of allergy or risk, analysis of IgE, evaluation of allergy suppressing activity, and drug screening.

[0131] The kit of the present invention may include materials for detecting the expression of the reporter gene, which may include, for example, when the reporter gene expresses an enzyme, a substrate for the enzyme, for example, a substrate for luciferase.

[0132] The kit of the present invention may, for example, comprise an incubation material used for incubating the cells of the present invention. The incubation material may mean a material used for incubating the cells, for example a medium or a buffer in which the cells are incubated. The incubation material may, for example, be an incubation material for sensitization incubation or an incubation material for cell response induction incubation. The incubation material may also be an incubation material for both sensitization and cell response induction.

[0133] The medium may be, for example, but is not limited to, MEM medium, which may contain supplementary components such as fetal bovine serum. The buffer can be, for example, but is not limited to, PBS, which can be used, for example, as a cell washing solution.

[0134] The kit of the present invention may include a cell sensitizing component. The component may be included in the incubation materials for the sensitizing incubation described above, for example in the medium or buffer. Alternatively, the component may be included in the kit without being included in the medium or buffer. The cell sensitizer may be a component capable of sensitizing the cells of the present invention. The cell sensitizer may be, for example, IgE or chimeric IgE. The IgE may be primate IgE, for example, human or non-human primate (especially monkey) IgE, and is preferably human IgE. The IgE may be purified or isolated IgE, or may be non-purified or non-isolated IgE. The chimeric IgE may also be, for example, chimeric IgE with a humanized Fc portion. The cellular material may be a biological material, such as whole blood, serum, plasma, or components contained in blood (eg, blood cells).

[0135] The kit of the present invention may contain a cellular response induction component. The component may be contained in the incubation material for the incubation for inducing a cellular response described above, for example, in a medium or a buffer. Alternatively, the component may be contained in the kit in a state where it is not contained in a medium or a buffer. The cellular response inducer component may be, for example, a component that binds to the cellular sensitizer to induce a response of the cell of the present invention, for example, a component that binds to the IgE or chimeric IgE. The cellular response inducer component may be, for example, an anti-IgE antibody, or an antigen or antigen candidate substance that binds (for example, specifically binds) to IgE or chimeric IgE. The cell response inducer, the antigen or antigen candidate substance, may be, for example, a substance that can cause an allergic reaction (particularly type I allergic reaction) in a subject (i.e., a substance that may become an allergen). Examples of such substances include, but are not limited to, dust; dirt; dandruff and other skin dander; pollen such as cedar pollen, alder pollen, grass pollen, and asteraceae pollen; fungi such as mold; insects such as midges and cockroaches; irritating or toxic substances contained in insects, seafood, and the like; substances contained in soybeans, eggs, wheat, milk, buckwheat, peanuts, shrimp, crab, and the like; substances contained in medicines such as penicillin; substances derived from the body of animals contained in excrement, and the like; plant substances such as flour and dust generated during wood processing; and other natural or chemically synthesized substances. For example, when it is desired to detect whether or not a subject is allergic to egg white, for example, refined products of substances present in egg white, such as ovalbumin, ovomucoid, and lysozyme, or egg white extracts can be used as the test substance. When chimeric IgE is used as the IgE, a low molecular weight hapten such as a nitrophenyl group can also be used as the antigen.

[0136] The kits of the invention may further include positive and / or negative control materials for use in the test. Positive control materials may include, for example, calcium ionophores (such as ionomycin). Negative control materials may be, for example, culture medium. The kit of the present invention may also contain a substance that inhibits the activity of a transcription factor, for example, a substance that inhibits the activity of NF-AT. The substance may be, for example, cyclosporine A or tacrolimus. When the kit of the present invention is a kit for screening an antiallergic substance, the substance may be used as a positive control for the antiallergic substance.

[0137] The kit of the present invention may further comprise an agent. The agent may be a sensitization inhibitor or an agent expected to inhibit sensitization. The agent may be, for example, a component that binds to IgE or chimeric IgE, such as an anti-IgE antibody or an anti-chimeric IgE antibody. The drug may be a cell response inhibitor or a drug expected to inhibit a cell response. The drug may be, for example, a signal transduction inhibitor that inhibits signal transduction caused by cross-linking of FcεRI.

[0138] The kit of the present invention may further include a container in which a reaction for testing is carried out, particularly a container having a space in which the cell of the present invention is retained. An example of the container is a well plate (such as a 96-well plate).

[0139] 7. Sixth embodiment (analysis method)

[0140] The present invention also provides an analytical method using the cells according to the present invention. The method can be performed for analysis or diagnosis of allergy. The method can include, for example, evaluating allergenicity, evaluating the presence or absence of allergy or the risk of allergy, analyzing IgE, evaluating allergy suppressing activity, or performing drug screening using the cells. That is, the analytical method of the present invention can be configured as a method for evaluating allergenicity, a method for evaluating the presence or absence of allergy or the risk of allergy, a method for analyzing IgE, a method for evaluating allergy suppressing activity, or a drug screening method.

[0141] The method of the present invention may be carried out, for example, to carry out the method described in the above-mentioned Patent Document 1, that is, to carry out the EXiLE method.

[0142] The method of the invention may also be carried out for secondary screening of antigen-specific IgE, for example to assess whether IgE is biologically significant, to assay for neutralizing antibodies, or to assay for cross-reactivity. Furthermore, the method of the present invention may be carried out for drug screening, particularly high-throughput drug screening. For example, the method of the present invention may be carried out for the selection or evaluation of a substance that inhibits the binding of IgE to FcεRI, or for the selection or evaluation of a substance that inhibits intracellular signaling in cells (particularly mast cells or basophils). The methods of the invention may also be performed for basic science research, for example for mechanistic analysis or biomarker discovery.

[0143] The method of the invention may, for example, comprise an incubation step of incubating a cell according to the invention and / or an analysis step of analyzing the response of said cells.

[0144] In the incubation step, for example, the cells according to the present invention may be incubated. The incubation step may consist of two or more incubation steps, as described below.

[0145] The incubation step may for example comprise incubating the cells according to the invention in an incubation material. In this specification, "incubation material" means a material used to incubate the cells, which may for example be a medium or a buffer in which the cells are incubated.

[0146] In the analysis step, the response of the cell according to the present invention may be analyzed. The analysis may be, for example, an analysis of the expression of the reporter gene described above. The expression of the reporter gene may be an expression induced by crosslinking between the aggregates described in "5. Fourth embodiment (cells)" above. A specific method for analyzing the expression of the reporter gene may be appropriately selected by a person skilled in the art depending on the type of the reporter gene. For example, when the reporter gene expresses an enzyme protein, the analysis step may analyze an enzyme reaction caused by the enzyme protein. For example, when the enzyme protein is luciferase, the luminescence generated by substrate decomposition by luciferase may be analyzed. For example, when the reporter gene expresses a fluorescent protein, the analysis step may analyze the fluorescence generated from the fluorescent protein.

[0147] The analysis may also be an analysis of an allergic response in the cells, in particular an analysis of a type I allergic response, in which an allergic response such as, for example, degranulation may be analyzed.

[0148] The analysis step may be performed after the incubation step, or may be performed while the incubation step is being performed. For example, the analysis step may be performed while any one of two or more incubation steps is being performed (particularly while the final incubation step is being performed).

[0149] In one embodiment of the present invention, the incubation step includes two incubation steps. Hereinafter, these two incubation steps are also referred to as a "first incubation step" and a "second incubation step". The first incubation step may be a sensitization incubation step in which a treatment is performed to sensitize cells according to the present invention. The second incubation step may be a cellular response induction incubation step in which a response is induced in the cells to which the treatment has been performed.

[0150] In this embodiment, the analysis step may be performed, for example, while the first incubation step is taking place, between the first incubation step and the second incubation step, while the second incubation step is taking place, or after the second incubation step.

[0151] Each of these steps will be described below.

[0152] (1-1) First incubation step

[0153] The incubation material used in the first incubation step may be a sensitizing material or a sensitizing analytical material. That is, the first incubation step includes incubating the cells in a sensitizing material or a sensitizing analytical material. The material may be, for example, a culture medium or a buffer. The type of the culture medium or the buffer may be appropriately selected by a person skilled in the art depending on, for example, the purpose of the analysis. For example, the culture medium may be an MEM medium. The material may contain auxiliary components, such as fetal bovine serum (FBS). The material may contain, for example, one or more antibiotics as auxiliary components.

[0154] As used herein, a "sensitizing material" refers to a material used to sensitize the cells. The sensitizing material may refer to a material that contains a component capable of sensitizing the cells (also referred to herein as a "cell sensitizing component"). The "cell sensitizer" is, for example, IgE or chimeric IgE. The IgE or chimeric IgE may be primate IgE or chimeric IgE, for example, human or non-human primate (particularly monkey) IgE or chimeric IgE, and is preferably human IgE or chimeric IgE. The IgE or chimeric IgE may be purified or isolated IgE or chimeric IgE, or may be non-purified or isolated IgE or chimeric IgE. The "material containing a component capable of sensitizing cells" may be, for example, a medium or buffer containing a cell sensitizing component, and in particular a medium containing the component. In one embodiment of the invention, the sensitizing material may be, for example, a material (particularly a culture medium or a buffer) containing purified or isolated IgE. In another embodiment of the present invention, the sensitizing material may be a material (culture medium or buffer) containing a biological component known to contain IgE (particularly a biological component derived from a primate, a biological component derived from a human or non-human primate (monkey)), and more specifically may be whole blood, serum, or plasma, or a material (culture medium or buffer) containing a blood component (e.g., blood cells).

[0155] In the present specification, the "sensitization analysis material" refers to a material that is the subject of an analysis to determine whether it can sensitize the cells. The sensitization analysis material may refer to a material that can contain the cell sensitizer. The "cell sensitizing component" may be as described above. The "material that may contain a cell sensitizing component" may be a material (culture medium or buffer) for which it is unknown whether it contains the component, or may be a material that is known to contain the component but the type or content of the component is unknown. For example, the material may be a material that is found to contain or not contain the component as a result of carrying out the method of the present invention, or a material for which the content and / or type of the component is known.

[0156] (1-2) Second incubation step

[0157] The incubation material used in the second incubation step may be a material for inducing a cell response or a material for analyzing the induction of a cell response. That is, the second incubation step includes incubating the cells in a material for inducing a cell response or a material for analyzing the induction of a cell response. The material may be, for example, a culture medium or a buffer. The type of the culture medium or the buffer may be appropriately selected by a person skilled in the art depending on, for example, the purpose of the analysis. For example, the culture medium may be an MEM culture medium. The material may contain auxiliary components, such as fetal bovine serum (FBS). The material may contain, for example, one or more antibiotics as auxiliary components.

[0158] In this specification, the "cell response-inducing material" may be a material containing a component that induces a cell response (hereinafter also referred to as a "cell response-inducing component"), particularly a component that induces a response of sensitized cells. The "cell response inducing material" may or may not contain the cell sensitizing component described above in addition to the cell response inducing component. The cellular response inducer component may be, for example, a component that binds to the cellular sensitizer to induce a response of the cell of the present invention, for example, a component that binds to the IgE or chimeric IgE. The cellular response inducer component may be, for example, an anti-IgE antibody, or an antigen or antigen candidate substance that binds (for example, specifically binds) to IgE or chimeric IgE.

[0159] The cellular response induced by the cellular response-inducing component may be, for example, expression of the reporter gene described above. In particular, the expression may be expression induced by crosslinking of the aggregates. The cellular response may also be an allergic response of the cell, particularly a cellular response related to type I allergy. The cellular response may be an allergic response such as degranulation.

[0160] In the present specification, the "material for cellular response induction analysis" refers to a material to be analyzed for its ability to induce a cellular response. The "material for cellular response induction analysis" may mean, for example, a material that may contain a cellular response-inducing component, and in particular, a material that may contain a component that induces a response of sensitized cells. The "cellular response inducing component" may be as described above. The "material that may contain a cell response-inducing component" may be a material (culture medium or buffer) for which it is unknown whether it contains the component, or may be a material that is known to contain the component but the type and / or content of the component is unknown. For example, the material may be a material that is found to contain or not contain the component as a result of carrying out the method of the present invention, or a material for which the content and / or type of the component is known.

[0161] (1-3) Analysis process

[0162] In the analysis step, the response of the cell is analyzed. The response may be, for example, the expression of the reporter gene described above. In particular, the expression may be an expression induced by crosslinking between the aggregates. A specific method for analyzing the expression of the reporter gene may be appropriately selected by a person skilled in the art depending on the type of the reporter gene. For example, when the reporter gene expresses an enzyme protein, an enzyme reaction may be analyzed in the analysis step. For example, when the enzyme protein is luciferase, luminescence generated by substrate decomposition by luciferase may be analyzed. For example, when the reporter gene expresses a fluorescent protein, a fluorescence analysis may be performed in the analysis step.

[0163] The response may be an allergic response of the cells, particularly a cellular response related to type I allergy, such as an increase in intracellular calcium ion concentration, degranulation, etc. These allergic responses may be measured using a fluorescent indicator. In order to analyze the response, the change in refractive index of the cell membrane accompanying the allergic response may be measured using an evanescent wave.

[0164] (1-4) Use of drugs

[0165] In the analysis method of the present invention, a drug capable of affecting the response in the cell of the present invention may be used. The drug may be, for example, an agent used to inhibit or suppress an allergic reaction, and may be, for example, a sensitization inhibitor or a cell response inhibitor. The drug may be, for example, Prior to the first incubation step, During the first incubation step, Between the first and second incubation steps, While the second incubation step is being carried out, or After the second incubation step It may be used in any one or more of the above steps. By carrying out the method of the present invention using the drug, it is possible to evaluate, for example, the allergic reaction suppression activity of the drug. Furthermore, by carrying out the method of the present invention using various drugs, drug screening can also be carried out.

[0166] The agent may be used, for example, in a state where it is contained in the incubation material described above. Examples of the use of the agent in each step are as follows.

[0167] For example, in the first incubation step described in (1-1) above, the drug may be included in the sensitization material or the material for sensitization analysis. In this case, the drug may be a sensitization inhibitor, or a drug expected to inhibit sensitization. The drug may be, for example, a component that binds to IgE or chimeric IgE, such as an anti-IgE antibody or an anti-chimeric IgE antibody. Alternatively, the drug may be a drug that induces downregulation of a receptor. By using the drug in this way, it is possible to screen for a drug that has an effect of suppressing an allergic reaction (particularly a type I allergic reaction), or to evaluate the suppressive effect of an allergic reaction suppressor (particularly a type I allergic reaction suppressor). Alternatively, the agent may be contacted with a cell sensitizer contained in the sensitizing material or the sensitizing analytical material before the first incubation step. After the contact, the screening or evaluation can also be performed by incubating the cells in the sensitizing material or the sensitizing analytical material.

[0168] In the second incubation step described in (1-2) above, the drug may be contained in the material for inducing a cell response or the material for analyzing the induction of a cell response. In this case, the drug may be a cell response inhibitor, or may be a drug expected to inhibit a cell response. The drug may be, for example, a signal transduction inhibitor that inhibits signal transduction caused by crosslinking of FcεRI. Examples of the drug include, but are not limited to, calcineurin inhibitors such as cyclosporine and tacrolimus; tyrosine kinase inhibitors such as Genistein, Herbimycin A, and Piceatannol; PLC inhibitors such as U73122; PI3-kinase inhibitors such as Wortmannin; and intracellular calcium ion chelators such as BAPTA-AM. By using drugs in this manner, it is possible to screen for drugs that have the effect of suppressing allergic reactions (especially type I allergic reactions), or to evaluate the suppressive effect of allergic reaction inhibitors (especially type I allergic reaction inhibitors). Alternatively, the agent may be contacted with a cell response inducing component contained in the material for inducing a cell response or the material for analyzing a cell response induction between the first incubation step and the second incubation step. After the contact, the screening or evaluation can also be performed by incubating the cells in the material for inducing a cell response or the material for analyzing a cell response induction.

[0169] (1-5) Example of allergenicity evaluation

[0170] In this example, the cellular response inducer component (particularly an antigen or a candidate antigen) used in the second incubation step is treated as a test sample, and the allergenicity of the cellular response inducer component can be evaluated.

[0171] In this example, in the first incubation step, the cells according to the invention are incubated in a sensitizing material comprising IgE or IgE-containing serum obtained from a subject (human), thereby sensitizing the cells with the IgE of the subject. Next, in the second incubation step, the sensitized cells are incubated in a material for inducing a cellular response containing an antigen as a test sample, whereby the antigen forms an aggregate as described above in the cell membrane of the cells according to the present invention, and the formation of the aggregate can result in the expression of, for example, a reporter gene. The cellular response is then analyzed in the analysis step. For example, the expression of the reporter gene can be analyzed in the analysis step. By analyzing the expression, the allergenicity of the antigen to the subject can be evaluated.

[0172] (1-6) Assessment of allergy risk or presence

[0173] In this example, the cell-sensitized component (particularly IgE or an IgE-containing biological component) used in the first incubation step is treated as a test sample, and the presence or risk of allergy (particularly type I allergy) to a specified antigen in the subject from which the cell-sensitized component is derived can be evaluated.

[0174] In this example, in the first incubation step, the cells according to the invention are incubated in a sensitizing material containing IgE or an IgE-containing biological component (particularly an IgE-containing serum) obtained, for example, from a subject (human), thereby sensitizing the cells with the IgE of the subject. Next, in the second incubation step, the sensitized cells are incubated in a material for inducing a cell response containing a predetermined antigen, which causes the antigen to form an aggregate as described above in the cell membrane of the cells according to the present invention, and the formation of the aggregate can result in the expression of, for example, a reporter gene. Next, in the analysis step, the expression of the reporter gene is analyzed. By analyzing the expression, the presence or absence, or the risk of the subject having an allergy to the predetermined antigen can be evaluated.

[0175] (1-7) Analysis of IgE

[0176] In this example, the cell sensitizer (particularly IgE or an IgE-containing biological component) used in the first incubation step is treated as a test sample, and the cell sensitizer itself can be analyzed.

[0177] In this example, in the first incubation step, the cells according to the invention are incubated in a sensitizing material containing IgE or an IgE-containing biological component (particularly an IgE-containing serum) obtained, for example, from a subject (human), thereby sensitizing the cells with the IgE of the subject. Next, in the second incubation step, the sensitized cells are incubated in a material for inducing a cell response containing a predetermined antigen, which causes the antigen to form an aggregate as described above in the cell membrane of the cells according to the present invention, and the formation of the aggregate can result in the expression of, for example, a reporter gene. Next, in the analysis step, the expression of the reporter gene is analyzed. By analyzing the expression, IgE can be evaluated.

[0178] (1-8) Method for evaluating allergy suppression activity

[0179] In this example, the drug is treated as a test sample, and the drug's activity in suppressing an allergic reaction can be evaluated.

[0180] In this example, in the first incubation step, the cells according to the invention are incubated in a sensitizing material which contains, for example, IgE or an IgE-containing biological component, in particular an IgE-containing serum, thereby sensitizing the cells with the IgE of the subject. Next, in the second incubation step, the sensitized cells are incubated in a predetermined material for inducing a cell response, whereby the antigen forms an aggregate as described above in the cell membrane of the cells according to the present invention, and the formation of the aggregate can result in the expression of, for example, a reporter gene. Here, a substance (drug) having or considered to have allergy-suppressing activity is contained in the sensitizing material or the material for inducing a cell response. When the substance is contained in the sensitizing material, the substance can act as a sensitization inhibitor. When the substance is contained in the material for inducing a cell response, the substance can act as a cell response inhibitor. Next, in the analysis step, the expression of the reporter gene is analyzed. By analyzing the expression, the allergy suppressing activity of the substance can be evaluated.

[0181] (1-9) Drug Screening

[0182] In this example, various drugs are treated as test samples, and the allergic reaction suppression activities of the various drugs are evaluated, and a drug having a better allergic reaction suppression activity can be selected.

[0183] In this example, in the first incubation step, the cells according to the invention are incubated in a sensitizing material which contains, for example, IgE or an IgE-containing biological component, in particular an IgE-containing serum, thereby sensitizing the cells with the IgE of the subject. Next, in the second incubation step, the sensitized cells are incubated in a predetermined material for inducing a cell response, whereby the antigen forms an aggregate as described above in the cell membrane of the cells according to the present invention, and the formation of the aggregate can result in the expression of, for example, a reporter gene. Here, each of various substances considered to have allergy suppressing activity is contained in the sensitizing material or the material for inducing a cell response. When the various substances are contained in the sensitizing material, the various substances are expected to act as sensitization inhibitors. When the various substances are contained in the material for inducing a cell response, the various substances are expected to act as cell response inhibitors. Next, in the analysis step, the expression of the reporter gene is analyzed when each of the various substances is used. By analyzing the expression, a substance having better allergy suppressing activity can be selected from the various substances.

[0184] 8. Working Example

[0185] (1) Synthesis of chimeric FcεRIα chain gene

[0186] A chimeric receptor gene (human-rat chimeric FcεRIα chain) in which the extracellular domain of human FcεRIα chain is linked to the transmembrane domain and intracellular domain of rat FcεRIα chain was created by artificial gene synthesis. The nucleotide sequence of the gene and the amino acid sequence encoded by the gene are shown in FIG. 4. In FIG. 4, the upper line shows the nucleotide sequence, and the lower line shows the translated amino acid sequence. The nucleotide sequence and amino acid sequence shown in FIG. 4 are the same as the nucleotide sequence of SEQ ID No. 1 and the amino acid sequence of SEQ ID No. 8, respectively. The relationship between the nucleotide sequence and amino acid sequence shown in FIG. 4 and the structure and function of the chimeric receptor protein is shown in FIG. 19.

[0187] As shown in Figure 19, of the amino acid sequence shown in Figure 4, amino acid residue numbers 1 to 25 form a signal sequence, amino acid residue numbers 26 to 205 form an extracellular domain, amino acid residue numbers 206 to 224 form a transmembrane domain, and amino acid residue numbers 225 to 246 form an intracellular domain.

[0188] The amino acid sequence of amino acid residues 26 to 205 constituting the extracellular domain is the same as the sequence shown in SEQ ID No. 10. The extracellular domain includes an IgE-binding region, and the IgE-binding region is composed of amino acid residues 110 to 183. The amino acid sequence of amino acid residues 110 to 183 is the same as the sequence shown in SEQ ID No. 14. As shown in FIG. 19, among the amino acid residues contained in the IgE-binding region, particularly S110, D111, W112, W135, W138, K142, I144, A151, Y154, W155, Y156, E157, W181, Q182, and L183 are amino acids involved in binding to IgE. Of these amino acids, K142, I144, A151, Y154, W155, Y156, and E157 form the first IgE-binding site, and S110, D111, W112, W135, W138, W181, Q182, and L183 form the second IgE-binding site.

[0189] Furthermore, amino acid residues 44 to 108 and 121 to 194 constitute an immunoglobulin domain.

[0190] The amino acid sequence of the transmembrane domain is that of the transmembrane domain contained in the rat FcεRIα chain. The sequence of amino acid residues 206 to 224 is the same as the sequence shown in SEQ ID No. 12. An example of a base sequence encoding the amino acid sequence of the transmembrane domain is the sequence shown in SEQ ID No. 5. As shown in FIG. 19, the transmembrane domain exerts binding to the γ chain, and the charged amino acid D219 is an amino acid that is particularly involved in binding to the γ chain.

[0191] The amino acid sequence of the intracellular domain is that of the intracellular domain contained in the rat FcεRIα chain. The sequence of amino acid residues 225 to 246 is the same as the sequence shown in SEQ ID No. 13. An example of a base sequence encoding the amino acid sequence of the intracellular domain is the sequence shown in SEQ ID No. 6.

[0192] The signal sequence is a signal sequence contained in human FcεRIα chain. The sequence of amino acid residues 1 to 25 is the same as the sequence shown in SEQ ID No. 9. An example of a base sequence encoding the amino acid sequence of the signal sequence is the sequence shown in SEQ ID No. 2.

[0193] The base sequence of SEQ ID No. 1 has been optimized in consideration of the codon usage frequency in rats for efficient gene expression in cultured rat cells. The base sequence before optimization is the base sequence of SEQ ID No. 15 shown in Figure 5. Comparing these two base sequences, the characteristics of the base sequence of SEQ ID No. 1 are explained below.

[0194] The codon adaptation index (CAI) of the base sequence of SEQ ID No. 15 is 0.72. On the other hand, the codon adaptation index of the base sequence of SEQ ID No. 1 for rat is 0.83. The higher the codon adaptation index, the more preferable it is, with a maximum of 1, preferably 0.8 or more, more preferably more than 0.8, which is considered to be good for a high gene expression level in cells. The nucleotide sequence of SEQ ID No. 1 has a higher codon adaptation index than the nucleotide sequence of SEQ ID No. 15 and is therefore more suitable for expression in rat cells. The codon adaptation index of the base sequence of the chimeric FcεRIα-chain gene of the present invention may be, for example, 0.7 or more, preferably 0.8 or more, more preferably more than 0.8, even more preferably 0.81 or more, or 0.82 or more. The codon adaptation index may be, for example, 1.0 or less, 0.99 or less, or 0.95 or less. The codon adaptation index can be used as a measure for estimating the relative expression level based on the bias of synonymous codon usage in highly expressed genes such as ribosome-related genes, from the correlation between the codon bias of these highly expressed genes and the codon bias of the observed gene. The codon adaptation index can be calculated, for example, according to the method described in PM Sharp and WH Li (Nucleic Acids Res. 1987 Feb 11; 15(3): 1281-1295).

[0195] In the base sequence of SEQ ID No. 15, the percentage of codons with a usage frequency (codon usage frequency when the highest codon is set to 100) of 91 to 100 is 47%. On the other hand, in the base sequence of SEQ ID No. 1, the percentage of codons with a usage frequency of 91 to 100 is 59%. A higher proportion of frequently used codons is considered to be better for a higher level of gene expression in a cell. The base sequence of SEQ ID No. 1 has a higher proportion of codons with a usage frequency of 91-100 than the base sequence of SEQ ID No. 15, and is therefore more suitable for expression in rat cells. In the chimeric FcεRIα-chain gene of the present invention, the proportion of codons with a usage frequency of 91 to 100 in cells (particularly non-human animal cells) in which the gene is expressed can be, for example, 40% or more, preferably 50% or more, more preferably 53% or more, and even more preferably 55% or more. The proportion can be, for example, 100% or less, 90% or less, 80% or less, 70% or less, or 60% or less.

[0196] The GC content of the base sequence of SEQ ID No. 15 is 45.53%, whereas the GC content of the base sequence of SEQ ID No. 1 is 51.05%. The higher the GC content, the longer the half-life of the transcript mRNA tends to be, which is favorable for a high gene expression level. Therefore, it is believed that the base sequence of SEQ ID No. 1 can achieve a higher gene expression level than SEQ ID No. 15. The GC content of the chimeric FcεRIα-chain gene of the present technology may be, for example, 40% or more, preferably 47% or more, and more preferably 50% or more. The GC content may be, for example, 80% or less, 70% or less, or 60% or less.

[0197] The nucleotide sequence of SEQ ID No. 15 contains two sequences (AGTACT) recognized by the restriction enzyme ScaI, whereas the nucleotide sequence of SEQ ID No. 1 does not contain said sequence. The chimeric FcεRIα-chain gene of the present technology may contain a restriction enzyme sequence, but preferably does not contain a restriction enzyme sequence.

[0198] The nucleotide sequence of SEQ ID No. 15 contains three cis-acting elements (GGTGAT) involved in splicing, one cis-acting element (AATAAA) which is a polyA signal, one cis-acting element (ATTTA) involved in destabilization of mRNA, and one cis-element (AAAAAAA) which is a polyA signal. On the other hand, the nucleotide sequence of SEQ ID No. 1 does not contain these cis-elements. Therefore, the nucleotide sequence of SEQ ID No. 1 has been deleted from it sequences that may be mistaken for splice sites, sequences to which polyA may be erroneously added, and sequences that may cause destabilization of mRNA. The chimeric FcεRIα-chain gene of the present technology may contain one or more of these cis-acting elements, but preferably does not contain these cis-acting elements.

[0199] The base sequence of SEQ ID No. 15 has a pair of inverted repeats, whereas the base sequence of SEQ ID No. 1 does not have any sequence, so that the formation of unwanted higher-order structures can be suppressed in the latter case.

[0200] (2) Introduction of chimeric FcεRIα chain genes into RBL-NL4 cells

[0201] As shown in FIG. 6, a nucleic acid (DNA) having a base sequence in which a "restriction enzyme BamHI recognition site (GGATCC)" and a "sequence for forming a KOZAK sequence (CACC)" are added to the 5' end of SEQ ID No. 1 and a "restriction enzyme EcoRI recognition site (GAATTC)" is added to the 3' end was artificially synthesized. The nucleic acid was inserted into a pcDNA3.1(+) vector (Invitrogen) having the two restriction enzyme recognition sites in a multicloning site, using the two sites. The vector into which the nucleic acid was inserted was prepared in large quantities by a method known in the art. The vector into which the nucleic acid was inserted was then linearized using BamHI and EcoRI.

[0202] RBL-2H3 cells (cell number: JCRB0023, JCRB Cell Bank, National Institutes of Biomedical Innovation, Health and Nutrition) were stably transfected with a nuclear factor activated T-cell (NF-AT)-dependent firefly luciferase expression vector (pHTS-NFAT, Biomyx) to obtain cells (hereinafter also referred to as "RBL-NL4 cells"). The linearized vector was transfected into the RBL-NL4 cells using Lipofectamine3000, and drug selection was performed using Hygromycin. Cloning was then performed by limiting dilution to obtain seven clones into which the chimeric FcεRIα chain gene had been transfected.

[0203] RBL-NL4 cells express the rat endogenous FcεRI α-chain gene, β-chain gene, and γ-chain gene, and therefore, by expression of the introduced chimeric FcεRI α-chain gene, the chimeric FcεRI α-chain protein generated by expression of the gene, that is, FcεRI associated with the β-chain and γ-chain, is functionally expressed on the cell membrane of the cells.

[0204] (3) Luciferase expression in cells transfected with the chimeric FcεRIα chain gene

[0205] The seven clones obtained in (2) above and RBL-NL4 cells were cultured, and the luciferase expression was confirmed when the cultures obtained were stimulated with ionomycin, anti-human IgE antibody, or specific antigen. Specifically, the confirmation was performed as follows.

[0206] Each clone and RBL-NL4 cells were cultured in MEM medium supplemented with 10% inactivated fetal bovine serum. The composition of the medium is as follows: MEM medium (Earle's salts (+), L-Glutamine (-); Gibco 11090) Fetal bovine serum (Gibco 10437-028, inactivated at 56°C for 30 minutes, concentration at time of use: 10%) GlutaMAX-I (Gibco 35050) Penicillin-Streptomycin (Sigma P4333) Geneticin (Gibco 10131, working concentration 500 μg / mL) Hygromycin B (Invirtogen 10687-10, working concentration 200 μg / mL) Penicillin and streptomycin were added to the medium to prevent bacterial infection, and geneticin and hygromycin B are selection markers.

[0207] The culture was carried out in a plastic cell culture flask (T25) at 37° C. in an incubator in the presence of 5% carbon dioxide.

[0208] The cells were subcultured as follows: the culture supernatant (containing floating cells) in the flask was decanted, and 5 mL of fresh medium was added. The cells were gently detached using a cell scraper and pipetted, and then 1 / 40 volume (0.125 mL) was added to a subculture flask containing 5 mL of medium in advance, and cultured at 37°C and 5% CO2 for 5 days. When culturing on a large scale for use in the various tests described below, a T75 flask and double the amount of medium (10 mL) were used.

[0209] The day before the test to confirm luciferase expression when the above stimulation was applied, the following procedure was performed. Specifically, purified human IgE (ab65866, Abcam) (final concentration 50 ng / mL) was added to the MEM medium. The medium was placed in each well of a white 96-well plate with a transparent plastic bottom (product number: 165306, Thremo). Then, cells of each clone were added at 5 × 10 per well. 4 The cells were seeded at 50 μL each and left to stand overnight in an incubator for sensitization. Additionally, cells from each clone were placed into each well of the 96-well plate and left overnight in the incubator in the same manner, except that no purified human IgE was added (i.e., unsensitized cells were also prepared).

[0210] The next day, the cells were washed several times with PBS. 100ng / mL of anti-human IgE antibody (product number A80-108A, BETHYL, final concentration 100ng / mL) prepared in the above medium was added to the wells containing the sensitized cells, and the cells were stimulated for 3 hours at 37°C. Similarly, 100ng / mL of anti-human IgE antibody was added to the wells containing the non-sensitized cells, and the cells were stimulated for 3 hours at 37°C. Additionally, 250 μM ionomycin was added to separate wells containing unsensitized cells, and the cells were stimulated for 3 hours at 37°C.

[0211] After the stimulation, 50 μL / well of substrate solution (One-Glo Luciferase Assay System, Promega) was added to each well and reacted for 5 minutes, after which the luminescence intensity was measured using a luminometer (GloMax, Promega). The measurement results are shown in FIG.

[0212] In Figure 7, the measurement results for the seven clones are shown under "HuRa-11," "HuRa-19," "HuRa-21," "HuRa-29," "HuRa-37," "HuRa-38," and "HuRa-40," respectively. The measurement results for RBL-NL4 cells are shown under "NL4."

[0213] In Fig. 7, black dots indicate the measured luciferase luminescence intensity (unit: CPS) (right axis: LUMINESCENCE (CPS)). In Fig. 7, each bar indicates the relative luminescence intensity when anti-human IgE antibody was added to cells not sensitized with human IgE (no IgE), when anti-human IgE antibody was added to sensitized cells and stimulated (aIgE), and when ionomycin was stimulated to unsensitized cells (Iono) (left axis: Luciferase activity (fold change)). The relative luminescence intensity is the relative luminescence intensity when the luminescence intensity of each clone without stimulation is set to 1, and is shown on a log scale.

[0214] As shown in Figure 7, a comparison of the sensitized (aIgE) and unsensitized (no IgE) cases shows that for all clones, the amount of luciferase expression increased several tens to 100-fold upon stimulation with anti-human IgE antibodies. On the other hand, RBL-NL4 cells not expressing the chimeric FcεRIα-chain gene showed almost no response to stimulation with anti-human IgE antibodies. This shows that the introduction of the chimeric FcεRIα-chain gene conferred the ability to detect human IgE.

[0215] As shown in Figure 7, the amount of luciferase expression in RBL-NL4 cells stimulated with ionomycin (Iono) was significantly higher than in the two cases where RBL-NL4 cells were stimulated with anti-human IgE antibody (no IgE and aIgE). Ionomycin is a substance that activates NFAT without passing through FcεRI. Therefore, it was confirmed that the luciferase expression system in RBL-NL4 cells functions normally due to the activation of NFAT.

[0216] Among the seven clones, HuRa-40 was particularly superior in terms of responsiveness to antibody stimulation, FcεRI expression level, and proliferation ability. HuRa-40 was deposited internationally with the National Institute of Technology and Evaluation (NPMD) under the accession number NITE BP-03230 on June 17, 2020.

[0217] (4) Confirmation of IgE binding ability to cells transfected with chimeric FcεRIα chain gene

[0218] For each clone, the binding of human IgE to the cell surface was measured by flow cytometry as follows.

[0219] First, for each clone, a cell sample was prepared that had been sensitized overnight with 50ng / mL human IgE and a non-sensitized cell sample. Next, each of these two types of cell samples was exposed to 1μg / mL human IgE on ice for 30 minutes to allow all FcεRI to be occupied by IgE. In addition, some of the non-sensitized cell samples were not exposed to human IgE on ice. Then, each sample was stained with FITC-labeled anti-human IgE antibody. In this way, the following three samples were prepared for each clone. Sample 1: No sensitization, no human IgE contact on ice, FITC staining Sample 2: No sensitization, human IgE exposure on ice, FITC staining Sample 3: Sensitized, exposed to human IgE on ice, stained with FITC

[0220] In addition, the above three samples were prepared for RBL-NL4 cells (negative control) and RS-ATL8 cells (positive control).

[0221] The FITC fluorescence intensity of the samples prepared as described above was measured by a flow cytometer. The measurement results are shown in FIG. 8. As shown in FIG. 8, the number of cells in which FITC fluorescence was confirmed increased in the order of samples 1, 2, and 3, and in particular, the number of cells in which FITC fluorescence was confirmed for sample 3 was significantly higher than for samples 1 and 2. Similar results were also obtained for the positive control RS-ATL8 cells. On the other hand, no such results were obtained for the negative control RBL-NL4 cells. These results confirmed that IgE specifically bound to the cells of each clone.

[0222] (5) Examination of test conditions suitable for the cells of the present invention

[0223] (5-1) Stimulation time

[0224] HuRa-40 cells were suspended in 10% FBS-containing MEM medium containing 100-fold diluted healthy human serum (Cosmo Bio Co., Ltd.), and plated at 5.0 × 10 4 Cells were seeded at 50 μL / well and incubated overnight in a CO 2 incubator.

[0225] After washing the sensitized cells, anti-human IgE antibody (0.1 μg / mL) diluted in MEM medium containing 10% FBS was added at 50 μL / well, and stimulation was performed for 1 hour, 3 hours, 6 hours, or 8 hours. For unstimulated cells, medium was added.

[0226] After the stimulation time had elapsed, 50 μL / well of the substrate solution from the ONE-Glo EX Luciferase Assay System (Promega) was added to each well and reacted for 5 minutes at room temperature in the dark. The luminescence intensity was then measured using a microplate reader (GloMax, Promega). The measurement results are shown in FIG.

[0227] The relative luminescence intensity (luciferase activity (fold change)) shown in FIG. 9 was calculated according to the following formula. Luciferase activity (fold change) = (Luminescence intensity of antibody-stimulated HuRa-40 cells at each time point - Luminescence intensity of medium) / (Luminescence intensity of HuRa-40 cells to which medium was added at 0 hours - Luminescence intensity of medium)

[0228] From the results shown in Fig. 9, the stimulation time is preferably 1 hour or more, more preferably 1.5 hours or more, and even more preferably 2 hours or more. The stimulation time may be preferably 8 hours or less, more preferably 7 hours or less, even more preferably 6 hours or less, 5 hours or less, or 4 hours or less. The stimulation time may be, for example, 1 hour to 8 hours, more preferably 2 hours to 8 hours, even more preferably 1.5 hours to 7 hours, 2 hours to 6 hours, 2 hours to 5 hours, or 2 hours to 4 hours, and particularly preferably 3 hours to 4 hours.

[0229] (5-2) Serum concentration

[0230] HuRa-40 cells were suspended in 10% FBS-containing MEM medium containing healthy human serum (Cosmo Bio) at various concentrations and plated at 5.0 × 10 4 Cells were seeded at 50 μL / well and sensitized overnight in a CO incubator. Five serum concentrations were used: 0 vol%, 0.01 vol%, 0.1 vol%, 1 vol%, or 10 vol%.

[0231] After washing the sensitized cells, anti-human IgE antibody (0.1 μg / mL) diluted in MEM medium containing 10% FBS was added in an amount of 50 μL / well, and stimulation was carried out for 3 hours. For unstimulated cells, medium was added.

[0232] After the stimulation time had elapsed, the luminescence intensity was measured as described in (5-1) above. The measurement results are shown in Figure 10. The relative luminescence intensity (luciferase activity (fold change)) shown in Figure 10 was calculated according to the following formula. Luciferase activity (fold change) = (Luminescence intensity of HuRa-40 cells at various serum concentrations - Luminescence intensity of medium) / (Luminescence intensity of HuRa-40 cells at 0% serum concentration - Luminescence intensity of medium)

[0233] From the results shown in Fig. 10, the serum concentration for sensitization is preferably 0.01% by volume or more, more preferably 0.1% by volume or more, even more preferably 0.5% by volume or more, 0.6% by volume or more, 0.7% by volume or more, 0.8% by volume or more, or 0.9% by volume or more. The serum concentration for sensitization may be, for example, 10% by volume or less, preferably 8% by volume or less, more preferably 7% by volume or less, even more preferably 6% by volume or less, 5% by volume or less, 4% by volume or less, 3% by volume or less, or 2% by volume or less. The serum concentration may be, for example, 0.1% by volume to 10% by volume, more preferably 0.5% by volume to 5% by volume, even more preferably 0.7% by volume to 3% by volume, and particularly preferably 1% by volume.

[0234] (5-3) Cytotoxicity

[0235] Cytotoxicity of human serum against HuRa-40 cells was evaluated using Cytotoxicity LDH Assay Kit-WST (Dojindo Laboratories) with the extracellular release of LDH as an index. The cells were cultured overnight in MEM medium containing human serum at various concentrations (0 vol%, 0.01 vol%, 0.1 vol%, 1 vol%, or 10 vol%), and the cell supernatant of the culture was seeded at 50 μL / well on a 96-well microplate. Working Solution included in the kit was added to each well at 50 μL / well, and a color reaction was carried out at room temperature for 30 minutes in the dark. Finally, Stop Solution included in the kit was added to each well at 25 μL / well, and the absorbance at 490 nm was measured using a microplate reader (iMark, Bio Rad). The measurement results are shown in FIG. 11.

[0236] FIG. 11 shows that there is no toxicity at a serum concentration of 1%, but toxicity occurs at a serum concentration of 10%.

[0237] (5-4) Cryopreservation

[0238] The effect of storage at -80°C on the phenotypic stability of HuRa-40 cells was examined. HuRa-40 cells were prepared before freezing at -80°C, after 2 months of freezing, or after 4 months of freezing. These three types of cells were sensitized overnight in MEM medium containing human IgE (ab65866, Abcam, final concentration 50 ng / mL). After the sensitization, the cells were washed three times with PBS. After the washing, the cells were stimulated with anti-human IgE antibody for 3 hours. Ionomycin (250 nM) was used as a positive control. After the stimulation, a substrate solution (One-Glo Luciferase Assay System, Promega) was added, and the luminescence intensity was measured. The measurement results are shown in FIG. 12.

[0239] The results shown in Figure 12 confirmed the stability of the receptor-specific response when frozen for at least 4 months. It was also confirmed that the cells were able to respond to the receptor-specific response even after storage at -80°C for 8 months.

[0240] (5-5) Passage number

[0241] HuRa-40 cells at passage 4 (P4) or passage 50 (P50) were sensitized overnight with serum from a cedar pollen allergy patient (specific IgE antibody titer of 100 or more). After the sensitization, each cell was washed with PBS and stimulated with cedar pollen allergen extract. After the stimulation, a substrate solution (Bright-Glo, Promega) was added and luminescence was measured. The measurement results are shown in FIG. 13.

[0242] From the results shown in FIG. 13, no significant difference was observed in the response to the cedar pollen extract between P4 and P50.

[0243] (6) Testing using serum from allergy patients (peanut allergy)

[0244] (6-1) Antigen-specific responses using sera from patients with various RAST scores

[0245] HuRa-40 cells were suspended in 10% FBS-containing MEM medium containing 100-fold diluted serum from healthy subjects or serum from peanut allergy patients with various RAST scores. The cells were then plated at 5.0 × 10 4 Cells were seeded at 50 μL / well and incubated overnight in a CO 2 incubator.

[0246] After washing the sensitized cells, various concentrations of allergen scratch extract (peanut) diluted in MEM medium containing 10% FBS were added to stimulate the cells at 37° C. for 3 hours. The same stimulation treatment was also carried out on cells that had not been sensitized.

[0247] After the stimulation time had elapsed, 50 μL / well of the substrate solution of the ONE-Glo EX Luciferase Assay System (Promega) was added to each well and reacted for 5 minutes at room temperature in the dark. The luminescence intensity was then measured using a microplate reader (GloMax, Promega). The measurement results are shown in FIG.

[0248] The results shown in FIG. 14 demonstrate that HuRa-40 cells respond in an antigen-specific manner.

[0249] (6-2) Comparison of the cells of the present invention with other cells

[0250] The antigen-specific response by HuRa-40 cells was compared with that of RS-ATL8 cells, with RBL-NL4 cells used as a negative control. RS-ATL8 cells are RBL-SX38 cells, which are RBL-2H3 cells stably expressing human FcεRI, and an NF-AT-dependent firefly luciferase expression vector (Biomyx) has been stably introduced thereinto. As described above, RBL-NL4 cells are host cells for HuRa-40 cells, and are RBL-2H3 cells stably transfected with an NF-AT-dependent firefly luciferase expression vector (Biomyx).

[0251] The three types of cells were each classified into two groups according to RAST score 6 (>100U). A The serum from a patient with peanut allergy (100-fold dilution) was suspended in MEM medium containing 10% FBS at 1.0 × 10 / mL, and the cells were placed in a 96-well microplate (ISOPLATE-96TC, PerkinElmer) at 5.0 × 10 4 Cells were seeded at 50 μL / well and incubated overnight in a CO 2 incubator.

[0252] After washing the sensitized cells, allergen scratch extract (peanut) diluted with MEM medium containing 10% FBS was added at various concentrations (0, 0.1, 1, 10, 100, or 1000 ng / mL) and stimulated at 37°C for 3 hours.

[0253] After the stimulation time had elapsed, 50 μL / well of the substrate solution from the ONE-Glo EX Luciferase Assay System (Promega) was added to each well and reacted for 5 minutes at room temperature in the dark. The luminescence intensity was then measured using a microplate reader (GloMax, Promega). The measurement results are shown in FIG.

[0254] The results shown in Figure 15 show that HuRa-40 cells exhibit superior antigen response compared to RS-ATL8 cells. Moreover, the responsiveness of HuRa-40 cells was superior to that of RS-ATL8 cells across a wide range of antigen concentrations.

[0255] (7) Comparison of the cells of the present invention with other cells (allergy testing, egg allergy)

[0256] The antigen-specific response by HuRa-40 cells was compared with that of RS-ATL8 cells, with RBL-NL4 cells used as a negative control.

[0257] The three types of cells were each suspended in MEM medium containing 10% FBS and serum from an egg allergy patient (specific IgE antibody titer of 100 or more) or pooled serum from healthy subjects, and then plated onto a 96-well microplate (ISOPLATE-96TC, PerkinElmer) at 5.0 × 10 4 Cells were seeded at 50 μL / well and incubated overnight in a CO 2 incubator.

[0258] After washing the sensitized cells with PBS, egg white allergen extract diluted in MEM medium containing 10% FBS was added at various concentrations (0.1, 1, 10, 100, or 1000 ng / mL) and stimulated at 37°C for 3 hours.

[0259] After the stimulation time had elapsed, 50 μL / well of the substrate solution of the ONE-Glo EX Luciferase Assay System (Promega) was added to each well and reacted for 5 minutes at room temperature in the dark. The luminescence intensity was then measured using a microplate reader (GloMax, Promega). The measurement results are shown in FIG.

[0260] The results shown in Figure 16 show that when serum from egg allergy patients was used, HuRa-40 cells showed superior responsiveness compared to RS-ATL8 cells. Furthermore, when pooled serum from healthy subjects was used, no response was observed to the egg white allergen extract. These results show that HuRa-40 cells show superior antigen-specific responsiveness compared to RS-ATL8 cells.

[0261] (8) Comparison of the cells of the present invention with other cells (evaluation of the effectiveness of allergic reaction inhibitors)

[0262] Omalizumab is a therapeutic agent for bronchial asthma, seasonal allergic rhinitis, and chronic urticaria. Omalizumab is a humanized anti-human IgE monoclonal antibody that inhibits the binding of IgE to high affinity receptors (FcεRI) and thereby suppresses the activation of inflammatory cells such as basophils and mast cells. It competitively inhibits the binding of human IgE to FcεRI and reduces the concentration of free IgE in serum. It does not bind to IgE that has already bound to FcεRI. The cells of the present invention can be used, for example, to evaluate the effectiveness of allergic reaction inhibitors such as omalizumab. Below, experiments and the results thereof showing that the cells can be used for the effectiveness evaluation are described.

[0263] HuRa-40 cells and RS-ATL8 cells were prepared. These cells were suspended in MEM medium containing 10% FBS, and various final concentrations of omalizumab (0, 0.001, 0.01, 0.1, 1, 10, or 100 μg / mL) were added to each of these cells. Thirty minutes after the addition, 50 ng / mL of human IgE was added and the cells were sensitized overnight.

[0264] The sensitized cells were washed three times with PBS, and then human IgE antibody was added thereto, followed by stimulation at 37° C. for 3 hours.

[0265] After the stimulation time had elapsed, Bright-Glo (Promega) substrate solution was added to each well at 50 μL / well and reacted for 5 minutes at room temperature in the dark. Then, the luminescence intensity was measured using a microplate reader (GloMax, Promega). The measurement results are shown in FIG.

[0266] From the results shown in FIG. 17, for RS-ATL8 cells, the luminescence intensity decreased slightly with an increase in omalizumab concentration from 0.1 μg / mL to 1 μg / mL, and further decreased with an increase from 1 μg / mL to 10 μg / mL. Furthermore, as can be seen from the figure, for RS-ATL8 cells, the 50% inhibitory concentration (IC50) of omalizumab is greater than 1 μg / mL. On the other hand, as can be seen from the figure, for HuRa-40 cells, a significant decrease in luminescence intensity was already observed when the omalizumab concentration increased from 0.1 μg / mL to 1 μg / mL. As can be seen from the figure, for HuRa-40 cells, the IC50 of omalizumab is less than 1 μg / mL. That is, HuRa-40 cells can detect the action of omalizumab at a lower concentration than RS-ATL8 cells. Therefore, it is evident that HuRa-40 cells are more suitable for screening of substances with anti-allergic activity than RS-ATL8 cells, and that the use of HuRa-40 cells enables more precise screening of substances with anti-allergic activity.

[0267] In addition, from the results shown in FIG. 17, for RS-ATL8 cells, when the omalizumab concentration was at its maximum (100 μg / mL), the luminescence intensity was only reduced to about 1 / 4 compared to 0 μg / mL. On the other hand, for HuRa-40 cells, the luminescence intensity at an omalizumab concentration of 100 μg / mL was significantly reduced to 1 / 30 or less compared to 0 μg / mL. In other words, compared to RS-ATL8 cells, HuRa-40 cells leave almost no background. This result also shows that HuRa-40 cells are more suitable for screening of substances with antiallergic activity compared to RS-ATL8 cells, and that antiallergic substances can be screened more sharply using HuRa-40 cells.

[0268] A similar test to the one described above was performed using cyclosporine A instead of omalizumab. Specifically, cyclosporine A at a final concentration of 0 to 1 μg / mL was added to RS-ATL8 cells or HuRa-40 cells, and 30 minutes later, 50 ng / mL of human IgE was added and sensitized overnight. After washing three times with PBS, the cells were stimulated with anti-human IgE antibody for 3 hours, and Bright-Glo was added to measure luminescence. The measurement results are shown in FIG. 18.

[0269] From the results shown in FIG. 18, in HuRa-40 cells, a tendency for suppression was observed with the addition of 0.1 μg / mL cyclosporine A, and, as in RS-ATL8 cells, the response was significantly suppressed with the addition of 0.5 μg / mL cyclosporine A.

[0270] (9) Stability and reproducibility

[0271] Phenotypic stability evaluation test and reproducibility evaluation test for frozen storage of HuRa-40 cells were performed as follows.

[0272] The luciferase assay used in these studies was performed as follows. Specifically, 1 / 100 vol. of patient serum or human IgE (ab65866, Abcam) (final concentration 50 ng / mL) was added to the HuRa-40 cell suspension medium, and 5.0 × 10 4 The cells were seeded in a 96-well plate (165306, Thermo) at 50 μL / well and sensitized overnight in a CO2 incubator at 37°C. After the sensitization, the cells were washed three times with PBS, and after the washing, 50 μL / well of egg white allergen extract or anti-human IgE antibody (A80-108A, BETHYL) (final concentration 100 ng / mL) prepared in the medium was added, and stimulation was performed for 3 hours at 37°C under CO2. The following substrate solutions were added at 50 μL / well and reacted for 5 minutes, and the luminescence intensity was measured with a luminometer (GloMax, Promega). <Substrate liquid> One-Glo Luciferase Assay System (Promega) One-Glo EX Luciferase Assay System (Promega) Bright-Glo (Promega)

[0273] (Evaluation of phenotypic stability of HuRa-40 1) HuRa-40 cells before freezing, after 2 months, 4 months, 6 months, or 2 years and 5 months of freezing were sensitized with Human IgE overnight. After washing three times with PBS, the cells were stimulated with anti-human IgE antibody for three hours. The luminescence intensity was measured by adding One-Glo Luciferase Assay System. The measurement results are shown in Figure 20. As shown in the figure, the stability of the receptor-specific response of HuRa-40 cells was confirmed for at least 2 years and 5 months.

[0274] (Evaluation of phenotypic stability of HuRa-40 2) HuRa-40 cells frozen for 2 months or frozen for 2 years and 5 months were sensitized overnight with serum from egg allergy patients (specific IgE antibody titer of 100 or more) or pooled serum from healthy subjects, washed with PBS, stimulated with egg white allergen extract, and the luminescence intensity was measured with the One-Glo EX Luciferase Assay System. The measurement results are shown in Figure 21. As shown in the figure, the stability of the receptor-specific response of HuRa-40 cells was confirmed for at least 2 years and 5 months.

[0275] (Inter-room reproducibility evaluation) The following study was carried out at two facilities (corresponding to A and B in Figure 22) and three trials (corresponding to EXP1, 2, and 3 in the same figure) (inter-laboratory collaborative study). Human IgE was added to HuRa-40 cells and sensitized overnight. After the sensitization, the cells were washed three times with PBS, and after the washing, they were stimulated with anti-human IgE antibody for three hours. A homogeneous luciferase substrate solution (Bright-Glo) was added and the luminescence intensity was measured. The measurement results are shown in Figure 22. As shown in the figure, the reproducibility of the test using HuRa-40 cells was extremely high.

[0276] (Indoor reproducibility evaluation) Reproducibility was confirmed in a single testing laboratory. Different lots of human IgE (corresponding to OLD and NEW in FIG. 23) were added to HuRa-40 cells and sensitized overnight. After the sensitization, the cells were washed three times with PBS, and after the washing, they were stimulated with anti-human IgE antibody for three hours. A homogeneous luciferase substrate solution (Bright-Glo) was added and the luminescence intensity was measured. The measurement results are shown in FIG. 23. As shown in the figure, the reproducibility of the test using HuRa-40 cells was extremely high. [Accession number]

[0277] Rat cells: NITE BP-03230

[0278] TIFF0007587745000016.tif175154

Claims

1. A first base sequence encoding the extracellular domain of the human FcεRI α chain; A second base sequence encoding at least the cell transmembrane domain of the non-human animal FcεRIα chain; A chimeric FcεRI α-chain gene comprising:

2. The chimeric FcεRI α-chain gene according to claim 1 , wherein the first base sequence comprises the base sequence of SEQ ID NO:

7.

3. The chimeric FcεRI α-chain gene according to claim 1 or 2, wherein the second base sequence comprises at least the base sequence of SEQ ID NO:

5.

4. The chimeric FcεRI α-chain gene according to any one of claims 1 to 3, wherein the second base sequence further comprises the base sequence of SEQ ID NO:

6.

5. The chimeric FcεRI α-chain gene according to any one of claims 1 to 4, further comprising a third base sequence encoding a signal sequence for expressing the chimeric FcεRI α-chain generated based on said gene on a cell membrane.

6. The chimeric FcεRI α-chain gene according to claim 5 , wherein the third base sequence comprises the base sequence of SEQ ID NO:

2.

7. The chimeric FcεRI α-chain gene according to any one of claims 1 to 6, wherein the chimeric FcεRI α-chain gene has the base sequence of SEQ ID NO:

1.

8. The chimeric FcεRI α-chain gene according to any one of claims 1 to 7, wherein the non-human animal is a rodent.

9. The extracellular domain of the human FcεRI α-chain; At least the transmembrane domain of the non-human animal FcεRIα chain; A chimeric FcεRI α-chain protein comprising:

10. The chimeric FcεRI α-chain protein of claim 9 , wherein the extracellular domain comprises the amino acid sequence of SEQ ID NO:

14.

11. The chimeric FcεRI α-chain protein of claim 9 or 10, wherein the transmembrane domain comprises the amino acid sequence of SEQ ID NO:

12.

12. The chimeric FcεRI α-chain protein further comprises an intracellular domain of a non-human animal FcεRI α-chain, The chimeric FcεRI α-chain protein of any one of claims 9 to 11, wherein the intracellular domain comprises the amino acid sequence of SEQ ID NO:

13.

13. The chimeric FcεRI α-chain protein according to any one of claims 9 to 12, wherein the chimeric FcεRI α-chain protein has the amino acid sequence of SEQ ID NO:

8.

14. A vector comprising the chimeric FcεRI α-chain gene according to any one of claims 1 to 8.

15. The chimeric FcεRIα chain gene according to any one of claims 1 to 8. A chimeric FcεRI α-chain protein according to any one of claims 9 to 13, or The vector of claim 14 . A cell of the non-human animal comprising:

16. The cell according to claim 15, further comprising a gene for the gamma chain of FcεRI of the non-human animal cell.

17. The cell according to claim 16, which forms an association comprising a chimeric FcεRI α-chain generated based on the chimeric FcεRI α-chain gene and a γ-chain of FcεRI of the cell.

18. The cell according to claim 17 , further comprising a reporter gene whose expression is induced by crosslinking of the aggregates.

19. An analytical kit comprising the cell according to any one of claims 15 to 18.

20. An analytical method using the cell according to any one of claims 15 to 18.

21. The analysis method includes: Incubating the cells; and an analyzing step for analyzing the response of said cells 21. The method of claim 20, comprising carrying out the steps of:

22. 22. The method of claim 21, wherein the incubating step comprises incubating the cells in an incubation material.

23. The analyzing step comprises: Evaluation of allergenicity, Analysis of IgE, Evaluation of allergy-suppressing activity, and Drug Screening 23. The method of claim 21 or 22, comprising performing at least one selected from the group consisting of:

Citation Information

Patent Citations

  • Method for examination of type i allergy

    JP2011019467A